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Colorectal cancer (CRC) is the third most deadly form of cancer in the Western world. 
Although screening efforts have reduced the overall mortality, the incidence is increasing 
among young adults. The frequency of inflammatory bowel disease (IBD) and obesity are 
increasing in parallel, which suggest a common underlying environmental link between the 
conditions. This increase is thought to correlate to an increased intake of high fat diets, and 
obesity is a major risk factor for CRC. Chronic inflammation, which is a hallmark for CRC 
promotion, is a well-known underlying factor in both obesity and IBD. The gut microbiota is 
another hallmark, and an impaired relationship between the host and gut microbes can 
contribute to obesity, IBD and CRC. The risk-benefit balance of current CRC-preventative 
treatments is poor, and there is a need for safer and better preventatives in order to reduce 
the CRC mortality. Both obesity and IBD place men at a significant higher risk of CRC 
compared to women. This indicates a protective role for estrogen. The use of full Estrogen 
receptor (ER) β knockout mice has demonstrated ERβ protective effects against 
experimentally induced CRC. However, it is unknown through which cells these protective 
effects are mediated. There are only low mRNA levels of ERβ in the colon, unclear if 
adequate for a functional role, and ERβ may also be expressed in intestinal immune cells. 
Understanding the CRC-preventative effects of intestinal epithelial ERβ in both sexes is 
important and may provide the background for a novel CRC chemopreventive approach.  
The overall aim of the thesis is the functional characterization of intestinal epithelial ERβ 
during colon inflammation and colitis-induced CRC and identification of potential sex 
differences, which can ultimately provide novel opportunities for chemopreventive 
exploitation (Figure 1).   
In paper I we utilized intestinal epithelial ERβ knockout mice (ERβKOVil) of both sexes 
and induced colitis and colitis associated CRC (CA-CRC). We found that intestinal 
epithelial ERβ is protective against colitis and CA-CRC in both sexes, but in a sex-
dependent manner. The underlying mechanism includes an intricate crosstalk with TNFα-
induced NFκB signaling.  
In paper II we identify that both sex and intestinal epithelial ERβ impact the microbiota 
composition. This may contribute to the exacerbated colitis and colitis-induced tumor 
formation observed in ERβKOVil mice.  
In paper III we induced colon inflammation by feeding the mice a high-fat diet (HFD, 
60%) for 13 weeks and explored treatment with estrogen receptor-selective ligands. We 
identified that estrogen signaling, via ERβ, modulated the HFD-induced changes in the 
colon microenvironment. This included sex-dependent effects on epithelial cell 




In paper IV we utilized paired-normal and CRC clinical samples and identified sex 
differences in the transcriptome of both normal colon and CRC. By applying data-driven 
feature selection and machine learning on sex-separated TCGA data, we proposed sex-
specific diagnostic biomarkers and prognostic biomarkers using survival analysis.   
In summary, this thesis characterizes intestinal epithelial ERβ as a novel chemopreventative 
target for CA-CRC in both sexes, and identifies related biological pathways, including 
crosstalk with nuclear factor κB (NFκB) signaling and modulation of circadian clock genes. 
ERβ activity in intestinal epithelial cells is manifested by altered microbiota composition, cell 
proliferation and immune cell infiltration. The identification of several significant sex 
differences provides evidence for the need to take sex into account in colitis and CRC 
research to improve health interventions.  
 
Figure 1: The aim of the thesis, built upon paper I-IV is to characterize the role of intestinal epithelial ERβ during colon 
inflammation and colitis-induced CRC, and identify potential sex differences, in order to provide novel opportunities for 
chemoprevention. Note: this image contains elements that were modified from Servier Medical Art 
(http://smart.servier.com/), licensed under a Creative Common Attribution 3.0 Generic License and <a 
href="https://www.freepik.com/vectors/medical">Medical vector created by brgfx - www.freepik.com</a>.  
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1.1 COLORECTAL CANCER 
Cancer is the second leading cause of deaths worldwide and in 2018 it accounted for 9.6 
million deaths of which 862 000 constituted of colorectal cancer (CRC) 1. Cancer is not a 
single disease; it is a group of diseases described by an abnormal cell growth with the ability 
to spread to other parts in the body. Normal cells transform into cancer cells essentially 
through mutations in their genes.  It is a multistage process, not a result from a single gene 
mutation, but rather the incorporation of several mutations. Mutations in genes controlling 
cell growth and survival, so called tumor suppressor genes and oncogenes might lead to 
uncontrolled cell growth, which can lead to cancer.  
1.1.1 Etiology  
CRC is the third most deadly form of cancer among both women and men in the Western 
world 2. Most colorectal tumors develop via multiple steps, including a series of 
morphological, histological and genetic changes that slowly accumulate in the course of time. 
CRC typically develops from benign, precancerous polyps, which are aggregations of 
abnormal epithelial cells within the intestinal mucosa. The theory behind CRC development 
is that it arises from stem or stem-like cells that reside in the crypt bottom 3. Cancer cells 
must acquire multiple mutations in order to develop into cancer. Genomic and epigenomic 
instability is a hallmark for CRC progression, which can lead to mutations and epigenetic 
changes in oncogenes and tumor suppressor genes, which facilitates the malignant 
transformation from adenomas to carcinomas 4.  
1.1.2 Genomic instability 
CRC is a heterogeneous disease with a number of genetic and epigenetic changes. Three 
molecular pathways leading to CRC have been identified including chromosomal instability 
(CIN), microsatellite instability (MSI), and CpG island methylator phenotype (CIMP) 
pathways 4. The CIN pathway is characterized by an imbalance in chromosome number and 
a high degree of loss-of-heterozygosity of tumor suppressor genes 5. MSI is characterized 
by defects in the mismatch repair (MMR) machinery 6. MMR is a conserved mechanism 
correcting for DNA replication errors and defects in this mechanism leads to alternate sized 
microsatellites and subsequent frameshift mutations in tumor suppressor genes 6. The 
majority of MSI-high tumors show a high tumor mutational burden (TMB) 7. The CIMP 
pathway is characterized by hypermethylation of CpG islands, which leads to silencing of 
tumor suppressor genes 8. One tumor can present characteristics of more than one pathway, 





Up to date, two distinct models for the transition of normal colon epithelium to CRC have 
been identified (Figure 2). They both transforms from normal epithelium to aberrant crypt 
foci, followed by early adenomatous polyps (adenomas) and progression to CRC 9. This 
process can take 10–15 years, but can progress more rapidly if there is a genetic 
predisposition, such as familial adenomatous polyposis (FAP) or Lynch syndrome 4. 
Adenomas are benign tumors and less than 10% of adenomas develop into CRC 10. The two 
morphological pathways include the classical pathway and the alternative serrated neoplasia 
pathway 9. In 1990, Fearon and Vogelstein proposed the model for the adenoma to carcinoma 
sequence, where certain mutations are associated with different stages of CRC progression 11. 
This classical pathway is the most common and has become a widely accepted standard for 
solid tumor progression. It is driven by CIN and involves the progression of tubular and 
tubulovillous adenomas, which can progress into adenocarcinomas 12. According to this 
model, mutation in the tumor suppressor gene adenomatous polyposis coli (APC) is the first 
event, leading to aberrant activation of Wnt/β-catenin signaling, followed by mutation in the 
oncogenic KRAS, and deletion of chromosome 18q and inactivation of the tumor-suppressor 
gene TP53 12. The serrated neoplasia pathway, on the other hand, is a more recent discovery. 
This involves the progression of serrated adenocarcinoma from serrated polyps. It arises from 
histological and molecular events different from tubular adenomas and is associated with 
mutations in the oncogene BRAF, with CIMP as a primary driving force and MSI as 
secondary driving force 13.  
 
Figure 2: CRC progression. The classical pathway involves CIN and is characterized by tubular adenomas and early 
mutations of APC, followed by mutations in KRAS and TP53 and LOH at chromosome 18q. The serrated pathway involves 
CIMP and BRAF mutations and MSI as secondary driving force and is characterized by serrated adenomas. 
1.1.4 Tumor staging and molecular classification  
CRC survival rates depend on the tumor stage at diagnosis. The tumor-node-metastasis 
(TNM) staging is the most common staging model used, and is based on the depth of tumor 
wall invasion, lymph node spread, and metastasis (Table 1) 14. However, TNM staging alone 
does not perfectly predict patient response to adjuvant chemotherapy, since patients with 
similar histopathology can present completely different outcome based on, for example, their 
genetic background. CRC is a very heterogeneous disease and characterizing the molecular 
subtypes of individual tumors are important for prognostic and therapeutic implication 15. Up 
to date, several models for different molecular subtypes have been described. Based on the 
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status of the main molecular defects, including CIN, CIMP, MSI, BRAF- and KRAS 
mutations, CRC has been divided into five molecular subtypes; type 1 (MSI-High, CIMP+, 
BRAF mutation, WT KRAS); type 2 (microsatellite stable (MSS) or MSI-low, CIMP+, 
BRAF mutation, WT KRAS ); type 3 (MSS or MSI-low, CIMP-, WT BRAF, KRAS mutation); 
type 4 (MSS or MSI-low, CIMP-, WT BRAF, WT KRAS ); and type 5 (MSI-High, CIMP-, 
WT BRAF, WT KRAS) 16. However, up to date, only a few genomic biomarkers are routinely 
used for treatment prediction in the clinic, including KRAS and BRAF mutational status and 
MSI status 17. KRAS mutational status is a marker for predicting resistance to anti-epidermal 
growth factor receptor (EGFR) drugs 17. MSI status is a predictor of immunotherapy due to a 
high TMB and a high load of tumor neoantigens 18. CRC patients with MSS tumors with high 
TMB may also benefit from immunotherapy. In fact, FDA recently approved 
pembrolizumab, an immunotherapy, for the treatment of all metastasizing solid cancers with 
high TMB (≥10 mutations/megabases) 19.  
Table 1: Staging of CRC based on TNM classification 14. T describes the tumor size and whether it has invaded nearby 
tissue. Tis stands for carcinoma in situ and refers to a group of abnormal cells that has not spread to surrounding tissue. N 
describes the degree of spread to regional lymph nodes. M describes the presence of distal metastasis. 
Stage T N M 
0 Tis N0 M0 
I T1-2 N0 M0 
IIA T3 N0 M0 
IIB T4a N0 M0 
IIC T4b N0 M0 
IIIA T1-2 N1/N1c M0 
T1 N2a M0 
IIIB 
T3-4a N1/N1c M0 
T2-3 N2a M0 
T1-2 N2b M0 
IIIC 
T4a N2a M0 
T3-4a N2b M0 
T4b N1-2 M0 
IVA Any T Any N M1a 
IVB Any T Any N M1b 








1.1.5 Tumor location 
Additionally, tumor location denotes an additional source of tumor heterogeneity (Figure 3). 
Left-sided (distal colon) and right-sided (proximal colon) CRC differ in their molecular 
characteristics, clinical outcome and treatment response 18. Right-sided CRC is more often 
found in women and characterized by sessile serrated adenomas whereas right-sided CRC is 
most often found in men and defined by traditional adenomas 20. While right-sided CRC 
patients tend to have more CIMP, MSI-high and BRAF-mutated tumors, left-sided CRC 
patients are associated with CIN, TP53 and APC-mutated tumors 20. Left-sided CRC patients 
have a better overall survival compared to right-sided, with better response to adjuvant 
chemotherapies such as 5-fluorouracil and targeted therapies such as anti-EGFR therapy 18. 
Right-sided CRC, respond poorly to conventional chemotherapies, but demonstrates 
promising response to immunotherapies 18. 
 
Figure 3: Characteristics of left-sided and right-sided CRC. Note: this image contains elements that were modified from 
Servier Medical Art (http://smart.servier.com/), licensed under a Creative Common Attribution 3.0 Generic License. 
1.1.6 Risk factors 
Not only genetic factors, but also environmental factors contribute to the etiology of CRC. 
Several risk factors, both modifiable and non-modifiable, have been recognized. The non-
modifiable risk factors include the individual susceptibility to develop CRC, and age is the 
most significant. The average age at diagnosis is 64 and more than 90% of the people 
diagnosed are older than 50 21. Other non-modifiable risk factors include family history and 
hereditary factors. Family history accounts for approximately 20-30% of patients with CRC 
22. The risk doubles in individuals with a first-degree family member diagnosed with CRC 
at 50-70 years of age, and triples if diagnosed before 50, and the risk further increases if 
there is two or more affected family members 4. Hereditary CRC syndrome accounts for 
approximately 10% of all patients and the most common one is Lynch syndrome, caused by 
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mutations in DNA MMR genes 4. The second most common is FAP, caused by mutations 
in the tumor suppressor gene APC 4. Inflammatory bowel disease (IBD), leading to chronic 
colitis is associated with an elevated CRC risk, which increases with the extent of IBD 23. 
However, the majority of CRC cases, around 70-80%, is sporadic and arises without any 
genetic predisposition 22. These are linked to environmental modifiable risk factors 10, 22, such 
as high-fat diets (HFDs), obesity, low physical activity, alcohol consumption, and smoking 24.  
1.2 COLITIS-ASSOCIATED CRC 
Chronic inflammation is a hallmark of cancer promotion and tumor growth, and promotes 
colitis-associated cancer through the production of oxidative stress, DNA damage, and 
accumulation of mutations and genomic instability 25. A variety of pro-inflammatory 
mediators trigger inflammatory responses, including tumor necrosis factor alpha 
(TNFα/TNF).  
1.2.1 Inflammatory bowel disease (IBD) 
IBD is a condition of chronic inflammation in the intestinal tract and the two most common 
subtypes of IBD are ulcerative colitis and Crohn’s disease. Ulcerative colitis is described by 
an inflammation that emerges in the rectum and extends proximally, but is rarely found in the 
small intestine. Crohn’s disease is described by inflammation in the entire gastrointestinal 
tract, with lesions primarily in the proximal colon and the small intestine. The precise 
etiology of IBD is unknown, however, it is multifactorial and driven by immune system 
disruption and/or an imbalanced interaction with the gut microbiota triggered by certain 
environmental factors in a genetically susceptible host 26. IBD patients present increased 
paracellular permeability, with tight junction (TJ) abnormalities 27-29, mucus abnormalities 30, 
31, and gut microbiota dysbiosis 32, 33. In addition, elevated TNFα levels, both locally and 
systemically, have been identified in patients with IBD 34, 35. 
IBD patients are at greater risk to develop colitis-associated colorectal cancer (CA-CRC), and 
20-30% of the patients will develop it at some point during their life 36. Moreover, CA-CRC 
presents a higher malignant potential compared to sporadic CRC 37. The pathophysiology of 
CA-CRC follows the inflammation-dysplasia-carcinoma sequence compared to the 
traditional adenoma-carcinoma sequence seen in sporadic CRC 38. The mutations in CA-CRC 
are similar to the ones found in sporadic CRC, however the timing of mutation acquisition 
differs between the two. In CA-CRC, TP53 mutations/deletions are early events and APC 
mutations, the driver mutation in sporadic CRC, occur later and are less frequent in CA-
CRC 38. This indicates that it is not the APC mutation per se that drives CA-CRC, but rather 
the downstream activation of oncogenic pathways, such as Wnt/β-catenin.  
Chemically-induced colon tumor animal models using azoxymethane (AOM)/dextran sodium 
sulfate (DSS) are widely used for studying CA-CRC. A single injection with the genotoxic 
colonic carcinogen AOM, followed by the chemical irritant DSS administrated in the 
drinking water, induces toxic effects on the colon epithelium and results in tumors with 
histological and molecular changes that closely resemble human CA-CRC. The molecular 
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alterations include alteration in β-catenin, increased levels of pro-inflammatory cytokines, 
including TNFα, and increased activity and nuclear translocation of NFκB. 39  
1.2.2 Obesity 
Epidemiological studies support that a high body mass index (BMI) increases the risk to 
develop CRC 40-42. Chronic inflammation is a well-established underlying factor in obesity 
and can promote tumor development 43. HFD increases this risk, and the incidence of CRC 
among young adults are increasing due to altered life-style factors 44. HFD feeding to mice 
has recently been identified as a model to study colon inflammation. Colon has been 
identified as the first organ to respond to HFD 45, with increased intestinal permeability, stem 
cell activity, inflammation, and altered gut microbiota 46-53. In addition, HFD-induced obesity 
has been shown to exacerbate CA-CRC development in mice 54.  
HFD feeding has also been shown to influence the circadian rhythmicity in the hypothalamus, 
adipose tissue, and liver, and to impair the normal eating behavior in mice 55. However, time 
restricted HFD-feeding restored the circadian metabolism and helped to prevent obesity and 
metabolic syndrome (MetS) 56. Hence, the circadian rhythm may be a major contributor in the 
pathogenesis of HFD-induced diseases. In fact, meta-analyses have revealed a correlation 
between night shift work, obesity, and an increased risk of CRC 57, 58.  
The frequency of IBD has increased in parallel with obesity, which suggests that there is a 
shared environmental link between the conditions. Adipose tissue produces pro-
inflammatory adipokines, which is a possible mechanism linking obesity and IBD 59; and 
circulating TNFα levels has been found to be higher in obese individuals 60. Another 
plausible mechanism linking the two conditions is the altered intestinal microbiota found in 
both obesity and IBD 59. However, it has been shown that HFD-induced changes in the gut 
microbiota in mice are independent of obesity 61, which implies that diet is a major 
manipulator of the gut microbiota.  
1.3 CIRCADIAN RHYTHMICITY 
The master clock in the suprachiasmatic nucleus coordinates the mammalian physiology in a 
24-h light-dark cycle. The circadian rhythm is fundamental for the sleep-wake cycle, which is 
orchestrated by the regulation of the hormone melatonin. The master circadian clock sends 
out signals to regulate gene expression in peripheral tissues 62. However, the peripheral 
tissues, such as the intestine, also possess self-sustaining circadian rhythms not regulated by 
the light-dark cycle, but regulated by food intake 62. The circadian rhythm in the intestine 
regulates a variety of biological processes, such as intestinal permeability, cell proliferation, 
immune homeostasis, gut microbiota, and metabolism, and its disruption can contribute to 




1.4 GUT MICROBIOTA 
The colon is inhabited by a tremendous number of bacteria, called the gut microbiota, which 
presents vital benefits to the host. The most abundant phyla belong to Firmicutes and 
Bacteroidetes, whereas other less abundant bacteria belong to Actinobacteria, Proteobacteria, 
Fusobacteria, and Verrucomicrobia 63. The gut microbiota produces short chain fatty acids 
(SCFAs) by fermentation of resistant starches and dietary fibers, synthesizes vitamin B and 
vitamin K, and convert primary bile acids (BAs) to secondary BAs 64. SCFAs, especially 
butyrate, are energy sources for intestinal epithelial cell (IEC) and modulates epithelial cell 
differentiation, proliferation and apoptosis 65. Additionally, SCFAs present important 
immunomodulatory functions and have been shown to increase mucus production, strengthen 
barrier function and inhibit inflammatory responses 66. In contrast to SCFAs, secondary BAs 
metabolized by the gut microbiota increase the risk for CRC, by induction of DNA damage 
and genomic instability 67. The gut microbiota is responsible for keeping intestinal 
homeostasis, and an impaired symbiotic relationship between the host and associated 
microbes, known as dysbiosis can contribute to obesity, IBD and CRC 68. Intestinal dysbiosis 
is proposed to be one of the leading causes of CA-CRC, by exacerbating chronic 
inflammation.  
A proper balance between anti- and pro-inflammatory pathways is important to maintain 
intestinal homeostasis. A remarkable feature of the intestinal immune system is its ability to 
tolerate luminal microbiota, but at the same time protect intestinal mucosa from pathogenic 
bacteria. In fact, the intestine has its own immune system called gut-associated lymphoid 
tissue (GALT), which account for nearly 70% of the entire immune system 69. The GALT 
consists of isolated lymphoid follicles surrounded by follicle-associated epithelium, forming 
the interface between the GALT and the lumen 70. The microbiota is important to shape the 
immune system and germ-free mice show defects in the development of GALT, in 
immunoglobulin A (IgA) antibody production, and present fewer lymphoid follicles 71.  
1.4.1 Intestinal homeostasis 
The epithelial lining of the colon consists of a single layer of diverse IEC (i.e. absorptive 
colonocytes, hormone-producing enteroendocrine cells, mucus-producing goblet cells and 
microfold (M) cells) 72, which are held together by adherent junctions and TJs and organized 
in crypts. The different cell types are generated from intestinal stem cells, located at the crypt 
base, whose progeny proliferate and differentiate into mature epithelial cells as they migrate 
up towards the luminal surface 72. The intestinal stem cells are protected from microbiota-
derived metabolites through the crypt structure, since the surface colonocytes absorb and 
reduce the levels of different metabolites before they reach the stem cells 73. The IEC together 
with the mucus layer generates a physical barrier, which protects the intestinal mucosa from 
pathogens in the intestinal lumen. This separation is crucial for a healthy relationship between 
the gut microbiota and the host. In addition, IEC mediates a crosstalk between the gut 
microbiota and intestinal immune cells by secretion of cytokines, chemokines and 
immunomodulatory molecules to coordinate immune responses and maintain intestinal 
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homeostasis (Figure 4). This crosstalk is mediated by expression of pattern-recognition 
receptors, including toll-like receptors (TLR), that respond to microbial products 72. TLRs are 
important to maintain tolerance to commensals but at the same time inducing inflammation 
against pathogens. The TLR functions are dependent on its subtype and cellular location. 
Activation of some TLR subtypes in the apical side of IEC is involved in maintaining a 
healthy intestinal barrier by secreting anti-inflammatory cytokines, enhancing antimicrobial 
peptide (AMP) production, TJ integrity, mucus secretion, and IEC proliferation and 
differentiation 74, 75. In addition, pathogen infiltration activates TLRs located on the 
basolateral side of the IEC and immune cells in the lamina propria, which induces secretion 
of inflammatory cytokines to activate the immune response 74. Activated pro-inflammatory 
macrophages (MΦ) are recruited to clear the bacterial infection and secrete cytokines and 
chemokines to recruit other immune cells, including neutrophils 76. The resident MΦ, on the 
other hand, persist during the inflammation and maintain their anti-inflammatory phenotype 
by secreting interleukin (IL)-10, which is crucial for the mucosal healing 76. A number of 
studies have shown that TLR-deficient mice are more susceptible to experimental-induced 
colitis and present increased intestinal permeability, bacterial burden, and inflammatory-
response 77-79. This emphasizes the gut microbiota as an important modulator of intestinal 
homeostasis.  
IEC also direct the adaptive immune response towards gut microbes, illustrated in figure 4, 
by transporting luminal antigens and bacteria, through M cells, to antigen-presenting cells 
(i.e. dendritic cells) in the lymphoid follicles, referred to as the immune sensors of the colon 
75. Antigen presentation to B and T cells in the lymphoid follicles contributes to antigen-
specific IgA production and T-cell response 75, leading to self-tolerance or immunological 
defense. IgA blocks bacteria and toxins from attaching to the epithelial cells, preventing 




Figure 4: Intestinal homeostasis. Microfold (M) cells sample bacteria from the lumen to antigen-presenting cells, i.e. 
dendritic cells (DC), in the lymphoid follicles. Antigen presentation to B and T cells leads to antigen-specific IgA production 
and T-cell response, leading to self-tolerance.  
1.4.2 Gut dysbiosis 
Gut dysbiosis is characterized by loss of beneficial bacteria, outgrowth of harmful 
pathogens, and loss of overall bacterial diversity. This can be caused by dietary changes, 
inflammation, infection or exposure to toxins or antibiotics 81. Generally, dysbiosis in 
obesity, IBD, and CRC is associated with a decrease of SCFA/butyrate-producing bacteria, 
with subsequent reduced levels of SCFAs 82, which can lead to enhanced intestinal 
permeability and inflammation. SCFA supplementation is protective against AOM/DSS-
induced CA-CRC 83. Reduced intake of dietary fibers, which are the main energy source for 
intestinal microbiota, can lead to outgrowth of bacteria that can utilize alternative energy 
sources, like mucin-degrading species. This can result in a disrupted mucosal barrier, 
increased bacterial translocation, and inflammation 84. Intake of HFD increases the levels of 
toxic secondary BAs, which exerts detrimental effect on the colon epithelium by inducing 
genotoxic effects, inflammation and proliferation 85. In addition, HFD increases the 
proportion of gram-negative bacteria, which correlates to increased levels of plasma 
lipopolysaccharide (LPS), an endotoxin that causes metabolic endotoxemia and eventually 
obesity-related disorders 52. LPS binding to TLR4 activates NFκB, which leads to increased 
expression of pro-inflammatory cytokines and results in increased intestinal permeability 52. 
The increase of reactive oxygen species (ROS) during inflammation disrupts the anaerobic 
environment in the gut, which can lead to dysbiosis by creating a selective advantage and 
overgrowth of facultative anaerobes or some aerobes 86. Intake of HFD has been shown to 
 
10 
increase the ratio of Firmicutes to Bacteroidetes 51. In addition, dysbiosis induces an excess 
growth of potential harmful bacteria in the gut, like the pathogen Enterobacteriaceae, 
belonging to the phylum Proteobacteria, which is one of the most commonly overgrown 
pathogens seen in IBD, obesity, and CRC 87. By secreting enterotoxins it induces intestinal 
permeability and damage to IEC, leading to intestinal inflammation 88. The altered 
microbiota metabolites, through release of toxic metabolites, seen in dysbiosis may be 
associated with neoplastic changes in IEC.  
1.5 TNFΑ/NFΚB SIGNALING  
TNFα plays a critical role in inflammation in both obesity and IBD, and is a target for 
biological treatments. TNFα is an early-response cytokine that controls several cellular 
processes, such as apoptosis, differentiation and cell proliferation, and production of 
inflammatory molecules, which are all linked to response to epithelial cell injury 89. TNFα 
act as a promoter of inflammation-associated cancer by activating the pro-survival 
transcription factor (TF) NFκB 90. NFκB is highly activated during many inflammatory 
conditions, and is a critical driving force of inflammation-induced cancer, by inducing 
several oncogenes and cytokines involved in carcinogenesis 91-93. Intestinal epithelial 
activation of NFκB leads to inflammation-induced CRC 94. 
The NFκB TF family consists of five subunits: c-Rel (REL), p65/NFKB3 (RELA, NFKB3), 
RelB (RELB), p105/p50 (NFKB1), and p100/p52 (NFKB2), that form transcriptionally 
active homo- and heterodimeric complexes. In unstimulated conditions, NFκB dimers are 
sequestered in the cytoplasm by interacting with IκB proteins. TNFα activates the canonical 
NFκB pathway, leading to activation of IκB kinase (IKK) complex, which phosphorylates 
the IκB proteins. The IκB proteins are then degraded, which allows nuclear translocation of 
the NFκB and subsequent transcription of its target genes 95. TNFα activation of NFκB 
increases, for example, the expression of myosin light chain kinase (MLCK), which 
increases the intestinal permeability 96. In addition, TNFα acts as a potent mutagen causing 
DNA damage via the production of ROS 97.  
Anti-inflammatory drugs are the most common treatment for patients with IBD, which also 
prevent the development of inflammation-induced CRC. Anti-inflammatory treatment with 
aspirin reduces the incidence of CRC in clinical trials 98, 99, by inhibiting NFκB nuclear 
translocation 94. However, the risk-benefit balance of using anti-inflammatory drugs, such as 
aspirin, remains poor and better preventive approaches are needed. In addition to aspirin, anti-
TNFα therapy is also used to treat patients with IBD. However, 30-40% of patients do not 
respond to this treatment, and an additional 30-40% may loose the response over time 100. 
TNFα can enhance epithelial wound healing, and several mouse studies have shown that 
depending on the inflammatory context, TNFα can also suppress intestinal inflammation. 
Reduced TNFα levels by antibody treatment or knockout in a mouse model of acute DSS-
induced colitis aggravated the severity of colitis 101. However, in contrast to the findings for 
acute colitis, reduced TNFα levels attenuated chronic DSS-induced inflammation 102 103. 
These studies indicate a beneficial role of TNFα during acute colitis but a detrimental effect 
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during chronic colitis. Several side effects of anti-TNFα treatment in IBD patients have 
been noted, including elevated risk of bacterial infection 104 and neurological complications 
105. The risk-benefit balance of current therapies to treat patients with IBD remains poor and 
there is a need to develop better and safer preventatives to reduce the prevalence of CA-
CRC.  
1.6 ESTROGEN SIGNALING 
1.6.1 Estrogen hormones 
Estrogens are a class of cholesterol-derived sex steroid hormones important for the function 
and development of female and male reproductive organs, and numerous other functions. In 
premenopausal women, estrogens are synthesized mainly in the ovary. Ovarian theca cells 
synthesize androgen, which is aromatized to estrogens by aromatase (CYP19A1) in 
neighboring granulosa cells 106. In males, estrogens are primarily synthesized in Leydig cells 
of the testis, where aromatase is expressed 106. Furthermore, aromatase is highly expressed in 
the placenta, and also expressed at lower levels in extra-gonadal sites, such as adipose tissue, 
muscles and brain, where estrogens also can be synthesized 106. There are three main forms of 
circulating endogenous estrogens (in order of potency): 17β-estradiol (E2), estrone (E1) and 
estriol (E3). E2 is the predominant circulating estrogen in premenopausal women 107. In men 
and postmenopausal women, the circulating estrogen levels are low, with E1 being 
predominant, mainly produced by aromatization of androgens in the adipose tissue 107. E3 is 
the predominant circulating estrogen during pregnancy, which is produced in large quantities 
by the placenta 107. An additional estrogen, estetrol (E4) is a weak estrogen also found only 
during pregnancy. It is exclusively synthesized in the fetal liver and enters the maternal 
circulation via the placenta 108. There are also minor endogenous estrogens, which do not 
require aromatase for their synthesis, such as the androgen metabolite 3β-diol, synthesized 
from dihydrotestosterone (DHT). Also, 3β-diol is important for the male reproductive system 
109. The schematic illustration of estrogen synthesis is visualized in figure 5. 
In addition to its critical role for the reproductive organs, estrogens play fundamental roles in 
various physiological functions. It is responsible for maintaining a normal function of the 
cardiovascular system 110, bone metabolism 111, energy metabolism 112, immune response 113-
115, and central nervous system 116. At the same time, estrogen signaling dysfunctions are 
implicated in numerous pathological conditions, including MetS 117, 118, autoimmune diseases 
119, cancers of the reproductive tissues, 120-122 and some cancers of the non-reproductive 
tissues, e.g. CRC 123. Estrogen, through regulation of cytokine production, can present both 
pro-inflammatory and anti-inflammatory properties, depending on the tissue context and dose 








Figure 5: Schematic illustration of estrogen synthesis, including the androgen metabolite 3β-diol.  
1.6.2 Estrogen receptors 
Estrogen mediates its effect via ERα, ERβ and the transmembrane G protein coupled estrogen 
receptor 1 (GPER1). ERα and ERβ belong to the nuclear receptor (NR) superfamily, which 
are a family of ligand-regulated TFs. Once activated, the nuclear ERs directly regulate gene 
transcription to control various biological processes, including inflammation, apoptosis, cell 
proliferation, metabolism, and development 125. Although the nuclear ERs mainly function as 
TFs, they have also been found to regulate different cellular functions in the cytoplasm 126.  
There are today 48 human NRs identified, which control numerous biological and 
pathological processes. They are ideal targets for drug discovery, and can be activated or 
inactivated by small lipophilic molecules, which can easily be substituted by a drug. Thirteen 





























Although the NRs have different functions and gene targets, they all share similar structures 
128-130. They consist of a variable N-terminal (domain A/B), a DNA-binding domain (DBD, or 
C domain), a hinge region (D domain), a ligand-binding domain (LBD or E domain) and a 
variable C-terminal (F domain) (Figure 6A). The LBD and DBD are highly conserved 
between all NRs and are linked together with the hinge region. The N-terminal on the other 
hand is highly variable and also harbor transcriptional activation functions, so-called 
activation function-1 (AF-1), which is ligand-independent. The LBD contains the activation 
function (AF-2), which is dependent on ligand binding and plays important roles for NR 
homo- and heterodimerization 131. In addition, NR binding to coactivators and corepressors is 
often mediated through one of its activation domains 130.   
ERα, encoded by the ESR1 gene located on chromosome 6, was discovered in 1958 132. The 
second ER, ERβ, encoded by the ESR2 gene located on chromosome 14 was discovered and 
cloned years later in 1996 133. ERα and ERβ are homologues, with highly similar DNA-
binding domains (97%) but variable ligand-binding and activation domains 130.  
ERs are evolutionary conserved between species, including human and mouse 134. However, 
splice variants of both the human and mouse ESR2 gene have been identified, which are 
species specific. Evidence suggests that there are five different ERβ isoforms in humans 
(ERβ1-5), which results from alternative splicing of exon 8, the last coding exon (Figure 6B) 
135. Structural analysis reveals that ERβ1, also referred to as ERβ wild type (WT), is the only 
full-length functional isoform with an intact LBD 135-137. Two major splice variants have been 
identified in mice, including ERβ1 (WT ERβ) and ERβ2 (ERβ_ins). The latter contains an 
18-amino acid insert in the LBD between exon 5 and 6 (Figure 6C) 134, 138. 
 
Figure 6: The structure of ERs. A) The ERs consist of five domains; A/B domain (N-terminal, ligand independent), C 
domain (DNA binding domain), D domain (hinge region), E domain (ligand binding domain) and F domain (C-terminal). The 
two ERs, ERα and ERβ share 97% sequence similarity in their DNA binding domain but variable ligand binding and 




1.6.3 ER signaling pathways  
The ER-dependent signaling can be initiated in the nucleus or in the plasma membrane 107, 
and divided into genomic and non-genomic signaling, based on whether the signaling 
regulates gene transcription. Estrogen activates ERs, but ERs can have activities also without 
ligands. Further, although the majority of estrogen signaling is mediated via ERs, ER-
independent signaling, where estrogen regulates enzymatic activities through other 
mechanisms, have also been observed (Figure 7) 107.  
1.6.3.1 Nuclear ER genomic signaling 
The main signaling pathway is mediated by ligand activation of the nuclear ERs, which leads 
to genomic effects (transcriptional regulation). Binding of ER ligands to the LBD of the 
receptors results in a conformational change, leading to dimerization of the receptors 
followed by DNA binding to the estrogen response elements (EREs) 139. Binding to EREs on 
the DNA leads to recruitment of co-activators or corepressors, which activates or suppresses 
gene transcription 139. Apart from acting directly through EREs to regulate the expression 
from ERE-containing promoters or enhancers, ERs can regulate gene transcription through 
tethering to other TFs, such as stimulating protein-1 (SP-1), activator protein-1 (AP-1) and 
NFκB 107. In addition to estrogen-dependent signaling, ligand-independent gene regulation 
has also been observed, where the ERs are activated through phosphorylation, by e.g. EGFR 
and IGF1R 107. 
1.6.3.2 Membrane ER signaling 
In addition to the genomic effects mediated by nuclear ER activation, some estrogen 
responses have been shown to be too rapid to be mediated by target gene transcription. Non-
genomic signaling is common for steroid hormones, including estrogens, and are most often 
associated with the membrane bound GPER1. However, ERα has also been found in the 
plasma membrane. The nuclear ERs do not contain a transmembrane domain and the ability 
of ERα to be localized to the plasma membrane is dependent on interaction with caveolin-1 
(CAV1), which is necessary for ERα transportation to caveolae rafts in the plasma membrane 
140. Another plausible mechanism may be due to palmitoylation of the receptor 140. The rapid 
signaling by membrane bound ERs regulate a variety of different cytoplasmic effects, 
including mobilization of intracellular calcium, cyclic adenosine monophosphate (cAMP) 
production, activation of membrane tyrosine kinase receptors (e.g. EGFR and insulin-like 
growth factor 1 receptor, IGF1R) and protein kinase signaling cascades 107, 139. The 
activation of protein kinase signaling cascades, such as cAMP/Protein kinase A (PKA), 
mitogen-activated protein kinase (MAPK)/extracellular signal-regulated kinase (ERK), 
Phosphoinositide 3-kinase (PI3K)/AKT can also result in indirect gene regulation by 
phosphorylation of TFs 107, 139. Membrane ERα signal transduction through P13K and ERK 
has been noted in mouse liver by the use of different ERα transgenic mouse models. The 
signal transduction through P13K and ERK were similar in WT mice and mice exclusively 




1.6.3.3 ER-independent signaling 
Altough the majority of estrogen signaling is mediated via ERs, estrogen can interact with 
enzymatic activities in the cytoplasm to exert antioxidant activities in an ER-independent 
manner. Estrogens antioxidant activities are mediated by its phenolic A ring, which allow it 
to regulate redox activities. Studies have shown that estrogen can reduce oxidative stress by 
preventing ROS release by damaged mitochondria 142. 
 
Figure 7: Estrogen and ER-mediated signaling pathways. There are four estrogen- and/or and ER-mediated signaling 
pathways. The first pathway is the estrogen-dependent nuclear ER signaling that mediates transcription of estrogen-
responsive genes with or without EREs. The second pathway is the estrogen-dependent membrane signaling, which initiates 
cytoplasmic effects by regulating membrane-based ion channels, tyrosine kinase receptors, regulating protein kinase 
cascades, and modification of transcription factors. The third pathway is the-ER independent signaling, where estrogen 
exhibit antioxidant effects. The fourth pathway is the ligand-independent ER signaling, where growth factors activate protein 
kinase cascades, which leads to phosphorylation of nuclear ERs. Note: this image contains elements that were modified from 





Endogenous estrogens activate the ERs, but many other compounds structurally similar to 
estrogen, referred to as xenoestrogens, can also activate ERs by binding to the LBD. These 
can be found in the environment and include natural phytoestrogens and synthetic estrogens 
143. Plant-derived phytoestrogens, such as the isoflavone genistein found in soy, have affinity 
for both ERs 144. Certain synthetic estrogens can be found in pesticides and plastics and can, 
when released into the environment as pollutants, interfere with the endocrine signaling, and 
are thus called endocrine disruptors 143. 
Based on their properties, ligands are divided into partial or full agonists, antagonists, and 
selective estrogen receptor modulators (SERMs). Agonists activate the ERs upon binding, 
whereas antagonists block the activation. SERMs are synthetic compounds, which modulate 
the action of ERs dependent on the tissue context. This provides the opportunity to selectively 
activate or inhibit estrogen actions in different tissues 143. Tamoxifen is a commonly used 
SERM, which possess anti-estrogenic activities in breast cancer and is used to treat ER+ 
breast cancer patients 145. At the same time it possess estrogen-like effects in other tissues, 
such as bone, where it protects against osteoporosis 145. Tamoxifen binds to both ERα and 
ERβ 146. In addition there is a group of antagonists referred to as selective estrogen receptor 
degraders (SERDs), which only presents anti-estrogenic effects. Fulvestrant is a well-known 
SERD, and by binding to ERs it inhibits E2 from binding, leading to a conformational change 
that impairs receptor dimerization 147. The fulvestrant-ER complexes are unstable and leads to 
ER degradation 147. Fulvestrant is used as a therapeutic strategy for advanced ER+ breast 
cancer 148.  
Estrogenic ligands can bind with equal affinity to the two nuclear ERs (e.g. E2), or present 
higher binding affinity for one of them due to their difference in LBD (59% homology, 
Figure 6A). This allows for selective modulation of estrogen action via ERα, ERβ, or both. 
The ERα-selective agonist Propylpyrazoletriol (PPT) and the ERβ-selective agonist 
Diarylpropionitrile (DPN) were utilized in the studies included in this thesis. PPT present a 
410-fold greater binding affinity for ERα compared to ERβ 149, while DPN has a 70-fold 
greater binding affinity for ERβ compared to ERα 150.  
Although ERα and ERβ share 97% similarity in their DBD (Figure 6A) and have similar 
activation mechanism, they exhibit different, sometimes opposing activities. For example, 
in breast cancer, ERα drives cellular proliferation 122, whereas in colon cells, ERβ is 
primarily anti-proliferative 151, 152. Their difference (18% homology, Figure 6A) in the 
activation domain, responsible for recruiting co-regulatory proteins, may contribute to such 
differences.  
Thus, selective activation of ERβ may be an ideal therapeutic candidate for CRC prevention 
that circumvents the adverse hormonal effects.  
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1.7 ESTROGEN AND CRC 
1.7.1 Epidemiological studies 
Several epidemiological studies support that estrogen is protective against CRC. Men have a 
higher incidence an earlier onset of CRC 153, and men with IBD have 60% higher risk of 
developing CRC compared to women 154. In addition, premenopausal women have a better 
overall survival compared to age-matched men and the reverse is seen in postmenopausal 
women 155. Furthermore, obesity is a stronger risk factor for CRC in men compared to 
women. A meta-analysis of 10 studies conducted by Frezza et al. showed that obesity placed 
men at a significantly higher risk of CRC compared to women 156, which indicates a 
protective role of estrogen in this context. Moreover, menopausal hormone therapy (MHT), 
oral contraceptives, endogenous estrogens and phytoestrogens lower the incidence of CRC 
157-161. MHT in women, has been reported to reduce CRC incidence with 20% 159, 162, 163, 
where estrogen alone renders the largest protective effect 164. Additionally, several 
epidemiological studies indicate that estrogen is protective against obesity and MetS. 
Menopausal transition is associated with significant weight gain, obesity, and increased 
prevalence of MetS, while MHT in women with diabetes has been proven to reduce obesity, 
insulin resistance, and fasting glucose levels 117, 118.  
1.7.2 ERβ and CRC 
MetS is a risk factor for CRC. In addition to epidemiological studies, animal studies suggest 
that females are protected against HFD-induced MetS and that estrogen treatment improves 
the condition 165-168. Moreover, males are more susceptible to AOM/DSS induced tumor 
formation 169, 170 and estrogen treatment in males reduced the severity of colitis and 
subsequent tumor formation 170. While both ERα and ERβ have been shown to be anti-
obesogenic, ERα has a clear role in improving the MetS, whereas the role of ERβ in this 
context is more debated. Loss of ERα leads to obesity, insulin resistance and impaired 
glucose intolerance in mice 171, 172. Although studies have shown protective effects of ERβ 
against HFD-induced MetS 173-175, Foryst-Ludwig et al. reported that ERβ indeed protects 
against HFD-induced obesity but also caused pro-diabetogenic effects, as full-body ERβ 
knockout (βERKO) mice presented improved glucose tolerance and insulin sensitivity 176.  
Most of the estrogen-mediated CRC protective effects, however, have been linked to ERβ. 
ERβ is expressed at low levels in normal IEC, declines to non-detectable levels during the 
progression of CRC 152, and polymorphism in the ERβ promoter region correlates with CRC 
risk and survival 177, 178. Moreover, several in vivo studies support that estrogen through ERβ 
mediates its CRC-protective effects. Female βERKO mice presented increased AOM/DSS-
induced tumorigenesis 179, and selective activation of ERβ in the APCMin model of intestinal 
tumorigenesis reduces colonic proliferation and tumor formation in both sexes 180. In 
addition, genistein supplementation, a phytoestrogen found in natural soy, reduced DSS-
induced colonic inflammation and permeability 181. Interestingly, genistein binds ERβ with a 
30-fold higher affinity compared to ERα 182. In line with this, ERβ has been suggested to 
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regulate the intestinal barrier since βERKO mice presents disrupted cell architecture and cell-
to-cell junctions 183. Anti-proliferative and anti-tumorigenic effects of ERβ have also been 
presented in human CRC cell lines and in xenografts 184. However, to date, it is unknown 
through which cells ERβ mediates its protective effect, since ERβ may also be expressed in 
intestinal immune cells. The role of intestinal epithelial ERβ during colitis-induced 
tumorigenesis has not been studied, and characterizing this mechanism is fundamental 
because selective activation of ERβ may provide novel opportunities for CRC 
chemoprevention.  
1.7.3 Estrogen and microbiota 
Recent advances have suggested a synergistic action between the gut microbiota and 
estrogens to impact obesity and cancer. Some bacterial species can metabolize estrogen-like 
compounds by secretion of β-glucuronidase, which deconjugates estrogen into its 
biologically active forms 185.  Soy isoflavones, such as genistein, is metabolized by the gut 
microbiota to compounds structurally similar to estrogen that can activate the ERs 185. In fact, 
the gut microbiota is one of the principle regulators of circulating estrogen, and the 
microbiota that is capable of metabolizing estrogens are referred to the estrobolome 185. 
Dysbiosis can lead to an impairment of deconjugation, which can impact the circulating 
levels of estrogens.  
The soy isoflavone genistein possesses antibacterial activities 144. Studies have shown that 
genistein supplementation can alter the gut microbiota composition in postmenopausal 
women by inducing the growth of the beneficial bacteria Bifidobacterium, which is involved 
in soy fermentation 186, 187. A meta-analysis conducted by Fang et al. showed that dietary 
supplementation with phytoestrogens in postmenopausal women significantly reduced insulin 
resistance 188. Dietary intake of phytoestrogens is also associated with reduced CRC risk 189.  
In addition to phytoestrogens, sex hormones can regulate the gut microbiota. A study by Zhao 
et al. showed that postmenopausal women have a lower species richness and diversity than 
premenopausal women 190. Moreover, several human and animal studies support that sex 
impact the gut microbiota although the results are inconsistent (reviewed in Kim et al. 2019) 
191, and the sex differences are more evident in patients with an enteric infection 192. 
Inconsistent results can be due to differences between mouse strains and housing conditions. 
Independent analysis of the gut microbiome from 89 different inbred mouse strains revealed 
that sex had an impact on the microbiota composition 193. The sex differences were indeed 
mediated by sex hormones since gonadectomized mice presented an altered gut microbiota 
under HFD-feeding in both sexes 193. In addition, the α-diversity was significantly different 
between the sexes only after puberty 194. Another study by Kaliannan et al. showed that intact 
females present significantly lower abundance of Proteobacteria, lower Firmicutes to 
Bactereoidetes ratio, higher abundance of Akkermansia and higher 
Bifidobacterium/Enterobacteriaceae ratio compared to ovariectomized (OVX) females and 
intact males fed a Western diet 195. Furthermore, the role of estrogen is supported since E2 
treatment reduced the levels of Proteobacteria in both males and OVX females and increased 
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the Bifidobacterium/Enterobacteriaceae ratio in OVX females 195. Moreover, LPS-related 
functional pathways were lower in females, E2-treated males and E2-treated OVX females, 
compared to intact males and OVX females 195. E2 treatment was also shown to impact the 
gut microbiota diversity in males with AOM/DSS induced CA-CRC 196.  
The impact of ERs to modulate the gut microbiota has not been well studied. However, one 
study using female βERKO mice, showed that ERβ impacts the gut microbiota composition 
in a diet-specific manner 197. Hence, it is possible that intestinal epithelial ERβ may modify 
the gut microbiota during colitis and CA-CRC and thereby impact the disease progression.  
1.7.4 Estrogen crosstalk with NFκB 
NFκB is highly active during colitis, and serve as a critical link between inflammation and 
CA-CRC 94. There is a lot of evidence that estrogen exerts anti-inflammatory activities, and 
ERs are known to interact with NFκB. E2 via ERα has been shown to block LPS induced 
nuclear translocation of p65 in the RAW 264.7 MΦ cell line 198. Moreover, E2-activated ERα 
and TNFα-activated NFκB have been shown to interact in both a repressive and a synergistic 
manner to regulate gene expression involved in cell proliferation and invasion and metastatic 
processes in MCF-7 breast cancer cells 199. In addition, TNFα has been shown to strongly 
modify the ERα enhancer landscape in a NFκB-dependent manner 200. Based on the 
homology between ERα and ERβ, and the finding that ERα can modify inflammatory 
responses through a crosstalk with NFκB in breast cancer, it is possible that ERβ may modify 
inflammatory signaling in the colon and thereby reduce the risk of cancer development. 
Interestingly, βERKO mice showed increased colonic activation of NFκB and iNOS 
production 179, and E2 treatment in males 170 and OVX females 201 inhibited the NFκB 
signaling pathway in AOM/DSS treated mice. In addition, NFκB has been shown to repress 





2 AIMS OF THE THESIS 
The overall aim of the thesis was to characterize the role of ERβ as a preventative target for 
inflammation and inflammation-induced CRC. An additional aim was to explore sex 
differences in the colon and CRC transcriptome.  
In order to achieve these aims, four studies were conducted, which will be referred to as 
paper I-IV throughout the thesis. The specific objectives are as follows: 
Paper I. Investigate the role of intestinal ERβ on inflammatory signaling and epithelial cell 
proliferation during colitis-induced (AOM/DSS) tumor formation in mice of both sexes, and 
to characterize potential sex differences.  
Paper II. Investigate the impact of colitis-induced tumor formation (AOM/DSS) and 
intestinal ERβ on the gut microbiota composition in mice of both sexes, and to dissect 
possible sex differences.  
Paper III. Investigate the role of estrogen signaling on the colon microenvironment during 
HFD-induced colon inflammation and to dissect potential sex differences.  
Paper IV. Identify sex differences in the colon transcriptome in normal and paired CRC 








3 MATERIAL AND METHODS 
3.1 ANIMAL EXPERIMENTS 
Ethical permission for all animal work in this thesis has been approved by the Animal Care 
and Use Committee and local ethical committee of the Swedish National Board of Animal 
Research. Mice lacking ERβ specifically in the intestinal epithelial cells (referred to as 
ERβKOVil) and two models to induce colon inflammation and/or tumor formation were used 
in order to characterize the role of intestinal epithelial ERβ on the colon and the colon 
microenvironment during colon inflammation and colitis-induced tumor formation. In paper 
I-II we utilized a CA-CRC mouse model and in paper III we utilized a mouse model of diet-
induced obesity. Using mouse models for studying human diseases have limitations, but mice 
are biologically very similar to humans and develop many of the same diseases. Critically, 
animal studies enable gene deletions and controlled dietary and genetic conditions, which is a 
necessity for this type of research. 
3.1.1 Mice 
ERβKOVil were generated using the Cre/lox system. Mice with the ERβ exon 3 flanked by 
two loxP sites, ERβflox/flox, were crossed with transgenic mice bearing cre recombinase 
expressed under the control of the enterocyte-specific Villin promoter. Cre is thus only 
expressed in the intestine where it performs site-specific deletion of the DNA sequence 
between the loxP sites. The deletion of ERβ exon 3 leads to a frameshift mutation and an 
early stop codon, with no resulting protein expression of ERβ. Littermates, ERβflox/flox lacking 
the Cre allele, were used as controls (referred to as WT). The mice were on a C57BL/6J 
background, and the genotype was confirmed with standard PCR protocol. The advantage of 
using ERβKOVil mice is the ability to characterize the role of ERβ specifically in the intestinal 
epithelium. Of note is that ERβ is also lost in the small intestine. Other male and female 
C57BL/6J mice were obtained from in-house breeding.  
3.1.2 AOM/DSS-induced colitis and tumor formation 
Five to 10-week-old ERβKOVil and WT mice of both sexes were injected once 
(intraperitoneal) at day one on the first week with 10mg/kg body weight (BW) of the colonic 
carcinogen AOM, followed by 2.5% of the colon irritant DSS in the drinking water for the 
second week. This was followed by two weeks of normal drinking water, before repeating the 
DSS cycle, three times in total. During the DSS cycles, the mice loose weight, get diarrhea, 
and rectal bleeding. The mice recover during the normal drinking water and eventually 
develop colitis and adenomas after three cycles. The mice were sacrificed after 9 or 15-16 
weeks after AOM injection. The AOM/DSS model closely resembles the pathological and 
molecular changes seen in human CA-CRC, and is a commonly used, highly reproducible 
method that can be used on mice with different genetic background. Another advantage with 
the DSS method is that different stages of the disease, both acute and chronic inflammation, 
can be studied depending on the concentration and frequency of DSS administration. One 
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limitation is the high AOM carcinogenic dose given to the mouse, which differs from the 
human situation where tumors usually develop from low exposure to carcinogens present in 
the environment during a longer time.  
3.1.3 High-fat diet (HFD)-induced colon inflammation 
Five to six-week-old male and female C57BL/6J mice were fed a HFD (60% kcal fat) or a 
matched low-fat (10% kcal fat) control diet (CD) for a total of 13 weeks. For the treatment 
with estrogenic ligands, the mice were injected every other day (intraperitoneal) for a total of 
9 injections for three weeks prior to sacrifice, with 0.05 or 0.5 mg/kg BW E2, 2.5 mg/kg BW 
PPT, 5 mg/kg BW DPN, or vehicle. The ligands were prepared in a solution of 40% PEG400, 
5% DMSO and 55% water. Compared to the AOM/DSS model, the HFD-model better 
resembles the human situation. However the diet used in this study does not accurately reflect 
the Western diet. An additional limitation with the HFD model is the common use of 
improper CDs that does not account for the fiber content. In this study, we used a matched 
CD with the same amount of fibers. Thus, our findings will accurately reflect the difference 
in the fat and carbohydrate content.    
3.1.4 Tissue collection 
Colons were harvested, washed, measured, opened along the long axis, and the number and 
size of the intestinal adenomas were recorded. The colons were then transferred to cryo-
embedding media (i.e. OCT), or fixed in 4% formaldehyde for 24h, stored in 70% EtOH and 
embedded in paraffin for histological analyses and immunohistochemistry (IHC), or snap 
frozen in liquid nitrogen for quantitative reverse-transcription PCR (qPCR) analysis. The 
sections were stained with hematoxylin and eosin (H&E) for colitis scoring by a pathologist 
blinded to the mouse genotype. Severity, degree of hyperplasia, degree of ulceration and 
percentage of the area involved were scored (0-3) generating colitis scores ranging from 0-12.  
3.2 ELISA 
Blood was collected at sacrifice by cardiac puncture using EDTA-treated tubes. Plasma was 
collected by centrifugation for measurement of E2 and insulin levels. The E2 assay is based 
on a competitive ELISA whereas the insulin assay is based on a sandwich ELISA. For E2 
measurements, anti-E2 antibody-coated wells are incubated with samples and E2 conjugated 
with horseradish peroxidase (HRP). During incubation, the HRP-labeled E2 competes with 
the endogenous E2 in the samples and the amount of the fixed HRP-labeled E2 decreases as 
the levels of endogenous estrogen increases. For insulin measurements, the ELISA is based 
on a capture antibody and a detection antibody. The insulin is first captured by the pre-coated 
wells with anti-insulin antibody and then detected by a biotinylated anti-insulin antibody. 
HRP is then added and forms a complex with the biotinylated antibody. A substrate is then 
added to the wells, which results in the development of a color and the absorbance is 
measured spectrophotometrically. As the absorbance is directly or inversely proportional to 
the amount of captured insulin and E2 in the samples, the amount can be derived from 
standard curves obtained from standards with known concentrations.   
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There is one limitation with measuring E2, without including E1. Circulating estrogen has 
been reported to increase with obesity and adipose tissue is the primary source of extra-
gonadal estrogen. However, the estrogen produced by aromatization of androgens in the 
adipose tissue is primarily E1 . E1 is also the predominant source of estrogen in men and 
postmenopausal women.  
3.3 RNA IN SITU HYBRIDIZATION  
ERβ expression in clinical samples was verified in the human protein atlas database, by 
immunohistochemistry (IHC) with the validated mouse monoclonal ERβ antibody 
(PPZ0506). The expression of ERβ is relative low; hence the mouse monoclonal antibody is 
not optional for detecting ERβ expression in mouse, since the secondary anti-mouse IgG 
antibody will detect endogenous mouse IgG antibodies, leading to a high background 
staining. For that reason we used RNA in situ hybridization (ISH) for the localization of Esr2 
mRNA in the colon tissue. This hybridization uses labeled complementary RNA to localize 
the mRNA sequence in the tissue. 
3.4 IMMUNOHISTOCHEMISTRY (IHC) 
IHC is a widely used antibody-based method to visualize antigens in a cell. We used the 
standard indirect Avidin-Biotin Complex (ABC) method to visualize the proliferative marker 
Ki-67 and the macrophage marker F4/80. First, an unlabeled primary specific antibody binds 
to the target antigen, followed by binding of the secondary species-specific biotinylated 
antibody to the primary antibody. The third layer involves the formation of a complex of 
avidin-biotin HRP, which can catalyze the oxidation of DAB to form a brown colorimetric 
product that can be visualized in light microscopy.  
In this thesis we used two different types of samples preparations: formalin fixed and paraffin 
embedded (FFPE) and frozen sections embedded in OCT. Both of these methods present 
advantages and disadvantages over one another. FFPE is better when it comes to storage and 
for morphological analyzes, since it preserves the tissue architecture by cross-linking. The 
conformations of proteins can be different in FFPE from frozen sections, where the proteins 
are preserved in its native stage, which affect recognition by antibodies. The frozen method is 
quicker and does not require antigen retrieval for reversing the cross-links to expose antigens. 
For the AOM/DSS animals we used FFPE, since we wanted to analyze the morphology of the 
tissue and score it for colitis.  For the HFD animals we utilized the frozen method, to avoid 
the problem with epitope masking for some of the antibodies we used.  
Before incubation with the primary antibody, the tissue needs to be blocked for unspecific 
staining, including endogenous peroxidase activity, endogenous biotin and for reactive 
epitopes. The blocking improves specific binding by the antibody. However, not all 
antibodies are specific for the epitope of interest. Thus, it is important to validate the 
antibodies and to include proper positive and negative controls. For these experiments, 
however, we used standard monoclonal antibodies that were the most cited. We verified that 
the staining pattern agreed with known expression, i.e. a confined F4/80+ staining in immune 
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cells between the intestinal crypts and a confined Ki67 staining in the nucleus of epithelial 
cells in the lower part of the crypts.  
3.5 EX VIVO EXPERIMENTS 
Small intestinal organoids were cultured from WT and ERβKOVil mice of both sexes to study 
how ERβ affect TNFα induced epithelial cell damage in isolated tissue, independent of the 
microbiota and immune cells. An organoid is defined as a miniature organ grown in vitro. 
The intestinal organoids were produced from stem cell-containing crypts and results in a 
three-dimensional structure of IEC, which resembles the in vivo organization with all 
different IEC types present when supplied with suitable exogenous growth factors and 
basement membrane scaffolding, in this case Matrigel. Collaborators performed this 
experiment. Primary organoids were cultured for 5-7 days, and treated with TNFα and/or 
DPN or equal amount of vehicle (DMSO), and number of de novo crypt domains per 
organoid was quantified. Quantification was conducted with coded sample identities and 
blind scoring. The disadvantage with this method is that we utilized small intestinal organoids 
instead of colonic organoids, and cannot draw strong conclusions how ERβ impacts 
regenerative growth and differentiation capacity in the colon. Although small intestinal 
cancer is rare in comparison to CRC, few studies have utilized colonic organoids, which may 
be due to the fact that colonic organoids are difficult to culture and maintain.  
3.6 IN VITRO EXPERIMENTS 
In order to elucidate the mechanism behind ERβ protective effects we utilized human CRC 
cell lines with or without (mock) lentiviral transduced full-length ERβ expression. One major 
limitation with using cell lines when investigating complex diseases, such as CRC, is the loss 
of tissue context and the influence of the tumor microenvironment. Another limitation is the 
study of ectopically expressed ERβ, which may not resemble the reality. However, cell lines 
are ideal for pure mechanistic studies, and comparing our mouse in vivo findings to our 
human CRC cell lines findings can validate molecular mechanisms.  
3.6.1 Cell culture 
CRC cell lines SW480 and HT29 mock and ERβ-expressing cells were cultured in normal 
cell culture media containing 5% fetal bovine serum (FBS) and 1% penicillin-
streptomycin.  Phenol red in the cell culture media is a weak estrogen and FBS contains low 
levels of estrogen, which can interfere with the response of exogenous estrogenic treatments. 
Therefore, the medium was changed to phenol red-free media with 5% dextran-coated 
charcoal (DCC)-treated FBS 24h before experiments, still including 1% penicillin-
streptomycin. DCC is used to reduce the levels of estrogen in FBS. The cells were treated 
with 10 nM E2, 10 nM DPN, 10 ng/ml TNFα, or vehicle for 24 h before luciferase assays. 
Cells were treated with E2 for 2h before ChIP experiments and treated with 10 ng/ml TNFα 
for 0, 30min or 2h before p65 WB experiments.  
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3.6.2 Luciferase assay 
The luciferase assay was used to determine if ERβ and NFκB impacted each other’s 
transactivation. A luciferase assay can be used to determine the ability of a protein to regulate 
gene transcription, but does not establish whether it is through DNA binding or through 
interaction with other protein complexes that can affect transcription. The estrogen response 
element (ERE) and NFκB response element (NFκB-RE) are placed upstream of the luciferase 
gene (LUC). Here we utilized the dual reporter assay and transfected the cells with ERE-
TATA-LUC or NFκB-RE-LUC reporter plasmids, with renilla luciferase control reporter 
plasmid as internal control. The expression of luciferase is measured in order to quantify the 
activity of the regulatory element. By adding luciferase assay reagent, firefly luciferase 
luminescence is generated and can be quantified. This reaction is then quenched and the 
renilla luciferase can be measured by adding another reagent to the same tube. The results are 
presented as firefly to renilla luciferase activity.  
3.6.3 WB p65 nuclear translocation 
TNFα activates the canonical NFκB pathway, leading to nuclear translocation of the NFκB 
heterodimer p65/p50 allowing transcription of its target genes. Here we separated the 
nuclear and cytoplasmic fractions to investigate if ERβ impacts the nuclear translocation of 
p65. The antibodies used were towards p65, α-tubulin (for cytoplasmic fraction) and SUN1 
(for nuclear fraction). The cell lysates were homogenized and the cytoplasmic and nuclear 
fractions were separated through sucrose cushion centrifugation, which gives rise to a 
cushioning effect and maintains the integrity of the nuclei. The nuclear lysate was washed 
and centrifuged to obtain the nuclear protein fraction. The nuclear and cytoplasmic protein 
fractions were loaded and separated by SDS-PAGE. The ionic detergent SDS denatures and 
binds to protein to give them an equal negative charge. When current is applied, the 
negatively SDS-bound proteins will migrate to the positive electrode and the proteins will be 
separated based on size as they migrate through the polyacrylamide gel. The proteins 
separated by size were transferred onto a PVDF membrane and blocked for unspecific protein 
binding with milk. The primary antibody is first added to the membrane, which binds the 
protein of interest, and a secondary antibody conjugated with HRP is added for detection of 
the primary antibody. Enhanced chemiluminescence (ECL) substrate was added and oxidized 
by HRP and the chemiluminescent signal was quantified. As this is an antibody-based 
method, non-specific protein detection is possible, due to similar epitopes. The α-tubulin and 
SUN1 antibodies were among the top-cited antibodies and are well characterized. α-tubulin is 
a monoclonal antibody, whereas SUN1 is a polyclonal antibody. Polyclonal antibodies are a 
mix of antibodies that recognizes different epitopes of the same antigen, which increases the 
risk for non-specific binding. However, we could validate our α-tubulin and SUN1 antibodies 
as they were only detected in the intended fractions. The p65 monoclonal antibody we used 
had only a few citations, but its specificity in WB has previously been validated by the use of 
p65 knockout.  
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3.6.4 Chromatin immunoprecipitation (ChIP) 
Unlike the transactivation assay, ChIP can be used to investigate protein and DNA 
interactions in a cell. By the use of ERβ ChIP-qPCR we could determine whether ERβ binds 
or is localized to specific genomic regions, such as promoter regions or other DNA-binding 
sites. DNA binding or associated proteins are first cross-linked to the DNA using 
formaldehyde. The chromatin is isolated and sonicated into short fragments before incubation 
with ERβ antibody or IgG antibody (control) attached to magnetic beads for 
immunoprecipitation. The immunoprecipitated ERβ-DNA cross-links are reversed followed 
by purification of the DNA. Primers for qPCR were designed to align to predicted ERβ-
binding sites, and negative control primer set was designed for a chromosome area where 
ERβ is not predicted to bind. Amplification of ERβ target sites were normalized to input from 
the same ChIP experiment (three independent experiments) and to Ct values of the negative 
controls and presented as fold enrichment. This is again an antibody-based method and it is 
important to have a validated antibody in order to produce reliable results. Here we use two 
negative controls, including the IgG ChIP and the ERβ ChIP performed in the Mock cells 
lacking ERβ to normalize our results, which will increase the signal-to-noise ratio. Moreover, 
the ERβ antibody used (PPZ0506) has previously been validated for ChIP in the lab (Indukuri 
et al., submitted) and is highly specific.    
3.7 CLINICAL SAMPLES 
Clinical samples (colorectal tumors and matched noncancerous adjacent tissue) were 
collected from patients (n=24, 18 women and 6 men) undergoing surgery in Stockholm. The 
study was approved by the regional ethical review board in Stockholm. In addition, gene 
expression for 641 (299 women and 342 men) CRC (COAD and READ) and 51 (28 women 
and 23 men) noncancerous mucosal tissues were downloaded from TCGA. The data were 
downloaded on 31st of January 2019 with the bioconductor package (31) from R via NCI 
Genomic Data Commons (GDC) data portal.  
3.8 QUANTATIVE PCR (QPCR) 
Frozen mouse tissues and clinical paired normal and CRC tissues stored in RNAlater were 
homogenized with a tissue lyser. RNA was isolated and purified and DNAse treatment was 
used to remove any genomic DNA. RNA was reverse transcribed to cDNA. Stool pellets 
from mice were homogenized and DNA was extracted. The cDNA or DNA was detected 
using qPCR. In qPCR, the amplification of the target sequence is monitored in real time and 
we used a fluorescent dye called SYBR Green, which binds to double-stranded DNA. 
Fluorescence can be quantified at the end of each amplification cycle to determine the 
amount of DNA that has been amplified. The cycle threshold value (Ct) is the number of 
cycles where the fluorescent signal is significantly greater than the background fluorescence. 
The Ct value is typically detected where the product amplification is exponential and the 
amount of product is doubled for each cycle. The Ct value is inversely proportional to the 
amount of target nucleotide sequence present in the sample. The Ct values are used to 
calculate the relative fold gene expression using the ΔΔCt method. The Ct value for each 
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sample is first normalized to a reference gene (i.e. ΔCt), which should be stable between 
samples and conditions. Next, the ΔCt difference between two experimental groups (ΔΔCt) is 
calculated. The fold change in the expression of the gene of interest between the experimental 
groups is then equal to 2-ΔΔCt. 
3.9 OMICS TECHNOLOGIES 
Omics technologies were applied in all four papers, in paper I, III, IV we used 
transcriptomics to study how sex and ERβ impact gene expression and in paper II we used 
16S rRNA-sequencing to study how sex and ERβ impact the gut microbiota community.  
In paper I, we utilized Illumina bead array for the transcriptomic analysis of two human 
CRC cell lines with and without ERβ expression and treated with TNFα (2h) to study how 
ERβ impact the TNFα-induced CRC transcriptome. In paper III and IV we used RNA-
sequencing with Illumina NovaSeq6000. In paper III we investigated how HFD, sex and 
estrogen signaling impacts the colon transcriptome and in paper IV we investigate 
deregulated genes in CRC compared to normal colon and study sex differences in the normal 
colon and CRC transcriptome.  
3.9.1 Illumina bead array 
RNA was prepared from triplicates of SW480 and HT29 CRC cell lines with and without 
ERβ expression and with and without 2h TNFα treatment. RNA was converted to labeled 
cRNA used for hybridization onto the Illumina Whole-Genome Gene Expression Direct 
Hybridization Array, with 25,559 probes included for analysis. After hybridization a scanner 
reads the signal and the relative expression levels for each gene are received by comparing 
the signals between different conditions. Lumi and limma packages were used to determine 
differentially expressed genes. Genes were considered as differentially expressed if P-
value<0.05 and log2FC>|0.4|. Gene ontology/biological function and subnetwork enrichment 
analysis were performed in Elsevier’s Pathway Studio (11.2.5.9).  
3.9.2 Illumina RNA-sequencing 
RNA from mouse colon tissue was prepared from 6 biological replicates from male and 
female fed with CD and HFD, and males fed with HFD and treated with E2 (0.5mg/kg BW). 
RNA from clinical samples (paired normal and CRC tumors) was prepared from 24 patients 
undergoing surgery in Stockholm. Library preparation was done with TruSeq Stranded Total 
RNA library preparation and rRNA was depleted with Illumina RiboZero. With this method, 
RNA is converted to cDNA, fragmented, and adapters are ligated to the end of the fragments. 
Single-stranded cDNA will hybridize to the flow cell through their adapter sequence. Once 
attached, cluster generation begins, which makes thousands of copies of each DNA fragment 
through bridge amplification, which will emit a signal strong enough for detection when 
sequenced. After cluster generation, all reverse strands are washed away leaving several 
million of dense clusters with identical sequences, and the sequencing can begin. A primer is 
attached to the forward strand and fluorescently labeled nucleotides are added and the first 
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labeled base is incorporated into the new DNA strand. Only one nucleotide can be 
incorporated at each run and a laser record the fluorescence after each run, and each base give 
rise to a different color. The process continues and the DNA sequence is analyzed base-by-
base. At least 17M paired-end reads (2x51bp in length) were generated for each sample. The 
reads were mapped against the mouse genome (GRCm38) or the human genome (GRCh37) 
using STAR. FeatureCounts and StringTie were used to generate gene counts, TPM and 
FPKM values. DESeq2 was used to calculate differentially expressed genes (DEG) with raw 
counts as input and the Benjamini-Hochberg procedure was used to estimate FDR. Genes 
were considered as significantly differentially expressed if P-value<0.05 and log2FC>|0.4| 
(mouse data) or P-adj<0.05 and log2FC>|2| (clinical data). Gene ontology/biological function 
was performed with DAVID bioinformatics website. 
3.9.3 16S rRNA-sequencing 
DNA was isolated from stool samples from WT and ERβKOVil mice of both sexes. 
Metagenomic studies are commonly performed on the 16S rRNA gene, which is 
approximately 1,500 bp in size and contain nine variable regions, located between several 
conserved regions. The variable regions are frequently used for phylogenetic classification. 
Library preparation is done in a two-step PCR process, where the variable V3-V4 genomic 
regions of bacterial 16S rRNA gene is first amplified in the primary PCR reaction. Next, 
Illumina adaptors are incorporation in the second PCR reaction. DNA was then denatured 
into single-stranded DNA that was sequenced as described above. An average of 7000 reads 
per sample were generated. The SILVA database was used for taxonomic assignment and 
changes in the microbiota composition were analyzed by rarefaction curves, alpha-diversity, 
Bray-Curtis divergence, and linear discriminant analysis (LDA) effect size (LEfSe). 
Permutational multivariate analysis of variance (PERMANOVA) was used for statistical 
analysis. Enriched features were determined with LEfSe, with a LDA threshold of 2.0 and a 
significance cutoff less than 0.05. Finally, phylogenetic investigation of communities by 
reconstruction of unobserved states (PICRUSt) software was used to predict the functionality 
of the metagenomic content, based on the abundance of corresponding operational taxonomic 
units (OTUs). The limitation with this study is the use of stool samples as a proxy for the gut 
microbiota, which is significantly different from the mucosa microbiota. Moreover, the 
microbiota changes along the GI tract due to differences in the environment, including pH, 
transit time, nutrient sources, mucin and bile acids, which again highlights the complexity in 
using stool as a proxy for the mucosal bacteria. However, due to the non-invasive sampling 
of stool it is easily translated into the clinic and therefore most of the gut microbiota research 
has been carried out in stool.  
3.10 FEATURE SELECTION METHODS 
CRC clinical samples were used for biomarker discovery. Feature selection was used to 
reduce the high dimension and noise produced by transcriptomic analysis to improve the 
identification of relevant CRC-related genes. FPKM values were used as input for feature 
selection using the Vita package in R (threshold for pvalues of 0). The features selected with 
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Vita were then either combined with the Boruta package or the mRMR package in R, with 
threshold for pvalues<0.01. Vita is a tree-based method that randomly splits the dataset into 
two equally sized subsets, and two random forests (RF) are trained using one of the subsets. 
Feature importance is then estimated based on the other, independent subset and the final 
importance value is calculated by an average of the two estimated scores for each variable. P-
values can be calculated based on the resulting empirical distribution. Boruta is a wrapper 
method built around the RF classification algorithm. It creates shadow features by replicating 
and randomly shuffles the original data. This shadow dataset is attached to the original data 
and then it trains a classifier on the dataset, i.e. RF. A feature is considered to be important if 
the importance score of the original data is higher than the highest importance score recorded 
among the shadow features. mRMR is a filter method that select features with a high 
correlation with the output (i.e. relevance), and a low correlation between themselves (i.e. 
redundancy). The features are selected one by one by maximizing the objective functions, a 
function of relevance and redundancy.   
3.11 MACHINE LEARNING 
The output from the feature selection was used as input for machine learning in order to rank 
the features based on importance. RF or adaptive boosting (AdaBoost) was used for 
classification modeling, to keep consistency with tree-based feature selection algorithms. The 
data was split so that one third was used to train the model and two third was used for testing 
the model, and the number of estimators used was set to 100.  
RF is a tree-based supervised learning model that splits the data into several decision trees, 
trained on different parts of the same training data and combined to improve the performance. 
In other words, several weak classifiers are put together to form a strong classifier. Each tree 
is built based on random extraction of observations and features from the dataset. Each tree is 
also based on a sequence of yes and no questions, which is based on single or combinations 
of features. At each node, a question is asked and the tree divides the data into two new 
branches (new nodes). This is repeated until you reach a leaf, i.e. when the node does not 
have any branches and the classifier successfully have split the data. The goal is to end up 
with features that split the observations so that the resulting groups are as different from one 
another as possible and that the members of each subgroup are as similar as possible.  
AdaBoost is a boosting algorithm, which uses an iterative approach to correct the errors from 
the weak classifiers to turn them into strong classifiers. Like RF, AdaBoost uses decision 
trees, but these trees consist of only one node and two leaves. AdaBoost uses a forest of such 
stumps rather than trees and can only use one variable to make a decision. The next tree is 
trained to take the previous tree´s mistakes into account and focuses on correctly classify the 
previously misclassified sample. It assigns higher weight to wrongly classified observations 
while putting less weight on those already classified well. This process is iterated until the 
data fits without errors or until it has reached the specified number of maximum estimators.   
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Synthetic minority oversampling technique (SMOTE) or randomly oversampling was used 
on the imbalanced TCGA data before classification. SMOTE works by drawing lines 
between existing minority samples in space, and creating new minority samples randomly 
along the lines. Randomly oversampling is based on randomly duplicating minority samples. 
Four different combinations were used and the accuracy, precision, recall and AUC were 
recorded for each combination.  
3.12 SURVIVAL ANALYSIS 
Scaled and mean-centered FPKM values together with living days were used as input for the 
survival analysis. High expression and low expression were defined as scale and mean-
centered FPKM values above zero and below zero, respectively. Kaplan-Meier curves were 
plotted in python and the significance was tested with log-rank test.  
3.13 STATISTICAL ANALYSIS 
GraphPad Prism was used for statistical analysis (GraphPad Software Inc). The results are 
presented as mean ±SEM. A (two-tailed) Welch's t-test or paired t-test (if paired data) was 
used for comparison between two groups. One-way and two-way analysis of variance 
(ANOVA) was used for comparison between multiple conditions followed by fisher's LSD 
test (in vivo data) or Tukey's multiple comparisons test. A p value <0.05 was considered 
being statistically significant (* p<0.05, ** p<0.01, *** p<0.001). # Indicates significant sex 
differences.   
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4 RESULTS AND DISCUSSION 
This section briefly summarizes the main findings of the four papers I-IV, which is a 
combined effort to dissect the role of estrogen signaling during colon inflammation and CRC. 
Detailed information can be found in the papers.  
4.1 PAPER I: INTESTINAL ESTROGEN RECEPTOR BETA SUPPRESSES 
COLON INFLAMMATION AND TUMORIGENESIS IN BOTH SEXES 
Several studies support a role for ERβ in CRC-preventative effects. However, its general 
expression and functions are controversial due to relative low mRNA levels in the colon and 
the use of unspecific antibodies in the literature. Further, support of the impact of ERβ on 
colitis and CA-CRC has been generated using βERKO mice or ERβ-selective agonists, hence 
it is unknown through which cells ERβ mediates its protective effects. ERβ is for example 
also expressed in immune cells, including B cells, T cells, and NK cells 203. Whether or how 
intestinal epithelial ERβ is protective against colitis and CA-CRC has not been examined and 
delineating this mechanism is crucial since selective activation of ERβ can provide novel 
opportunities for CRC chemoprevention. In order to define the role of intestinal epithelial 
ERβ during CA-CRC we utilized mice lacking ERβ specifically in the intestinal epithelial 
cells (ERβKOVil) and induced colitis (9 weeks treatment) and CA-CRC (15-16 weeks 
treatment) using AOM/DSS.  
First, we demonstrated ERβ expression in human colonic epithelial cells and lack of 
expression in CRC using a validated ERβ antibody, which reveals the clinical relevance to 
study the role of ERβ as a chemopreventive target against CA-CRC. Next, we showed that 
ERβ acts protective against AOM/DSS-induced tumor formation in mice, in a sex-dependent 
manner (Figure 8). ERβKOVil male mice developed significantly more tumors compared to its 
WT counterpart, whereas ERβKOVil female mice presented significantly larger tumors 
compared to WT females. Moreover, ERβKOVil mice showed a significant increase of TNFα 
and NFκB target genes, especially in males. Whereas ERβKOVil females presented increased 
ulcerated areas and delayed ulcer healing, which may be explained by the impaired epithelial 
proliferation required for intestinal regeneration. Furthermore, we showed that intestinal 
epithelial ERβ could suppress TNFα-induced signaling in vitro using human CRC cell lines 
and protect against TNFα-induced epithelial cell damage ex vivo in mouse intestinal 
organoids. We could thus dissociate the effect from the systemic immune response and the 
microbiota and determined a local interaction between intestinal epithelial ERβ and TNFα-
signaling. In fact, ERβ counteracted the TNFα-induced NFκB signaling both in vitro, in 
human CRC cell lines, and in vivo. Our mechanistic experiments revealed that while ERβ did 
not impact the transactivation of TNFα or the p65 nuclear translocation, TNFα enhanced the 
transactivation of ERβ. Interestingly, our chromatin immunoprecipitation (ChIP)-qPCR 
experiments showed a mechanism whereby ERβ directly binds to cis-regulatory chromatin 
region of key NFκB regulators. ERβ enhanced the expression of activating transcription 
factor 3 (ATF3), a negative regulator of NFκB, by binding to an assumed enhancer. ERβ 
further attenuated the positive regulators of NFκB, including B-cell lymphoma 3-encoded 
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protein (BCL3), and baculoviral IAP repeat containing 3 (BIRC3) by binding close to the 
promoter. We thus suggest that ERβ attenuates TNFα-induced effects by direct suppression 
of NFκB-induced inflammatory genes, including monocyte chemoattractant protein-1 (MCP-
1/CCL2) and macrophage inflammatory protein-1β (MIP-1β/CCL4), through binding and 
modulation of NFκB regulators. CCL2 and CCL4 are chemoattractants of MΦ and T cells, 
and intestinal epithelial ERβ may thus impact recruitment of immune cells, which in turn can 
impact colitis and CA-CRC.  
 
Figure 8: Intestinal epithelial ERβ protects against AOM/DSS-induced tumor formation in both sexes, by reducing the 
number of tumors in males and the size of the tumors in females. A p value <0.05 was considered statistically significant (* 
p<0.05, ** p<0.01). # Indicates significant sex differences. 
In conclusion, our results show for the first time that intestinal epithelial ERβ protects against 
CA-CRC in both sexes and determine a possible mechanism, involving an intricate crosstalk 
between intestinal epithelial ERβ and TNFα-induced NFκB signaling (Figure 9). TNFα 
enhances ERβ activation and ERβ, in turn, represses the NFκB-signaling by binding and 
regulating NFκB modulators. The subsequent reduced inflammatory signaling is manifested 
by reduced secretion of the chemoattractants CCL2 and CCL4, which in turn can cause less 
recruitment of TNFα-secreting pro-inflammatory MΦ. We thus suggest an inhibitory 
feedback mechanism where the protection is mediated in a dual manner: 1) ERβ reduces the 
intrinsic inflammatory signaling in the colon itself, which leads to 2) reduced immune cell 





Figure 9: Schematic illustration of the proposed model for ERβ attenuated CRC development. Intestinal epithelial ERβ 
reduces TNFα signaling through direct mediated regulation of NFκB regulators, leading to suppression of NFκB-induced 
inflammatory signaling, including less secretion of CCL2 and CCL4, which can lead to reduced recruitment of pro-
inflammatory TNFα-secreting macrophages and reduced tumor formation. Note: this image contains elements that were 
modified from Servier Medical Art (http://smart.servier.com/), licensed under a Creative Common Attribution 3.0 Generic 
License. 
4.2 PAPER II: COLITIS-INDUCED COLORECTAL CANCER AND INTESTINAL 
EPITHELIAL ESTROGEN RECEPTOR BETA IMPACT GUT MICROBIOTA 
DIVERSITY 
As mentioned in paper I, there are several studies that support a protective role of ERβ in the 
pathogenesis of CA-CRC. In the previous paper we showed that intestinal epithelial ERβ 
protects against CA-CRC in both sexes, in a sex-dependent manner, through an intricate 
crosstalk with ERβ and TNFα-induced NFκB signaling. We thus demonstrated that ERβ 
could modulate the response of TNFα regardless of the microbiota composition and immune 
response in vitro and ex vivo. However there are evidence that both E2 and genistein 
regulates the gut microbiota 187 186 195 and intestinal epithelial ERβ may modulate the gut 
microbiota during colitis and CA-CRC, which could contribute to the enhanced progression 
of CA-CRC seen in the ERβKOVil mice. In order to characterize the impact of intestinal 
epithelial ERβ on the microbiota composition during CA-CRC we performed 16S rRNA 
sequencing on stool samples collected at sacrifice.  
First we showed that AOM/DSS treatment significantly reduced the α-diversity (Figure 10A). 
Further, we noted a significant compositional dissimilarity caused by treatment. The gram-
negative bacteria Akkermansia (phylum Verrucomicrobia) and Mucispirillum involved in 
mucin degradation and Parasutarella (phylum Proteobacteria) were increased during colitis. 
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Interestingly, a reduction of SCFA-producing bacteria including Lachnospiraceae and 
Ruminococcaceae (phylum Firmicutes) was also seen. Functional prediction of the altered 
microbiota upon treatment revealed pathways involved in immune system disease and 
metabolism, including starch and sucrose metabolism. Furthermore, since ERβKOVil mice 
showed a sex-dependent increase of colitis-induced tumor formation in paper I, sex 
differences in the microbiota composition might contribute to this. Interestingly, we noted a 
significant compositional dissimilarity between sexes at baseline, which disappeared with 
treatment. Females showed significant higher levels of Bifidobacterium, which have been 
associated with health benefits in the intestinal tract and is widely used as probiotics 204. The 
probiotic Bifidobacterium animalis subsp. lactis strain BB12 protects against DSS-induced 
colitis by reducing TNFα-mediated intestinal epithelial cell apoptosis 205. Functional 
prediction showed that the female enriched microbiota impacted metabolism of cofactors and 
vitamins and the endocrine system. In males we found an increase of the mucus-degrading 
bacteria Mucispirillum and several SCFA-producing bacteria. Worth noting is that the 
significant increase of pathogenic Parasutarella upon AOM/DSS treatment were specific for 
males, and Parasutarella is known to increase in patients with Crohn’s disease. Both 
Mucispirillum and Parasutarella can secrete LPS, which can impact colitis and CA-CRC 
through TLR signaling. Studies have shown that males present increased LPS-related 
functional pathways compared to females, which are reduced upon E2 treatment during 
Western diet consumption 195. These microbiota-related sex differences might contribute to 
the sex differences noted in colitis-induced CRC in paper I.  
 
Figure 10: (A) AOM/DSS treatment and loss of intestinal epithelial ERβ reduces the α-diversity during 16weeks treatment. 
(B) Intestinal epithelial ERβ presents significantly altered taxa abundance during 9weeks treatment, including increased 
abundance of the sulfate reducing bacteria Desulfovibrio.  
Interestingly, we noted a significant compositional dissimilarity in ERβKOVil mice compared 
to WT mice during colitis. This difference decreased during CA-CRC, but ERβKOVil mice 
presented the lowest α-diversity during CA-CRC (Figure 10A). ERβKOVil mice displayed 
increased levels of many SCFA-producing Firmicutes families and increased levels of the 
gram-negative major sulfate reducing bacteria (SRB) Desulfovibrio (phylum Proteobacteria) 
during colitis (Figure 10B). Functional prediction revealed that ERβKOVil mice presented 
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alterations in energy metabolism, including enhanced carbohydrate metabolism, and 
decreased bacteria impacting the endocrine system. Increased levels of SCFAs such as 
butyrate can inhibit intestinal stem cell proliferation 73. Thus the increased levels seen in 
ERβKOVil mice may inhibit stem cell proliferation, and fail to repair the DSS-induced ulcers, 
which reflects what we observed in the ERβKOVil female mice in paper I, a delayed ulcer 
healing. Another interesting finding is the noted increase of the SRB Desulfovibrio in 
ERβKOVil mice. This strain belong to the main producers of hydrogen sulfide (H2S), which 
can be detrimental to the colonic epithelium because it impairs DNA repair and inhibits 
butyrate oxidation 206. IEC can starve without butyrate oxidation since it represent 70% of the 
total energy requirement 206, which may contribute to increased intestinal permeability and 
impaired intestinal homeostasis. The impaired butyrate oxidation in ERβKOVil mice may lead 
to SCFAs accumulation, inhibition of stem cell proliferation, and thereby contribute to the 
impaired ulcer healing seen in ERβKOVil female mice in paper I. In addition, H2S can reduce 
disulfide bonds in the mucin, exacerbating mucin degradation 207, and lead to an impaired 
intestinal barrier. However, we did not measure the levels of SCFAs or H2S in the stool, and 
we did not look at the mucosal-associated microbiota or metabolites. Performing such assays 
would provide an improved understanding of the impact of the gut microbiome on the colon. 
In conclusion, we show for the first time that intestinal epithelial ERβ modulates the gut 
microbiota, including bacteria involved in metabolism, during AOM/DSS-induced colitis, 
which may impact intestinal homeostasis and contribute to the CA-CRC progression.  
4.3 PAPER III: HIGH-FAT DIET AND ESTROGEN IMPACT THE COLON AND 
ITS TRANSCRIPTOME IN A SEX-DEPENDENT MANNER 
In paper I and II we showed that intestinal epithelial ERβ protected against colitis and 
subsequent tumor formation in both sexes. A major risk factor for CRC is obesity and 
consumption of a Western diet, and the incidence of CRC is increasing in young adults. 
Colon has been identified as the first organ to respond to HFD, with increased 
inflammatory signaling, intestinal permeability, stem cell activity and altered gut 
microbiota 45-53, which could contribute to CRC. Obesity is a risk factor for CRC in both 
sexes, however, this association is stronger in men compared to women 208, which indicates 
a role for estrogen. Understanding the impact of estrogen signaling during HFD-induced 
colon inflammation may improve our understanding of ERβ as a preventative target against 
CA-CRC. In order to dissect this, mice of both sexes were fed a HFD (60% fat) or a matched 
control diet (CD, 10% fat) for 13 weeks and treated with different ER-selective ligands for 
the last three weeks prior to sacrifice.  
First we demonstrated major sex differences in the colon transcriptome, especially during 
CD. The genes responsible for the sex differences during CD belonged to pathways involved 
in immune response and cell proliferation. Less distinct sex differences were seen during 
HFD, but common for both dietary conditions were sex differences involved in 
circadian/rhythmic processes, including the core clock genes Npas2 and Arntl (Bmal1), which 
were higher expressed in females compared to males. As we identified large sex differences 
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during CD it was not a surprising finding that the sexes responded differently to HFD in 
terms of colonic gene expression, with less than 10% in common. Interestingly, HFD 
impacted circadian clock genes, genes involved in oxidation-reduction and inflammatory 
responses in both sexes. Some of the sex-specific genes belonged to common pathways, such 
as cell proliferation, cell adhesion, migration, angiogenesis, and immune system, whereas 
some genes were involved in pathways tied to sex. Cell cycle, hypoxia and glucose 
homeostasis were specifically enriched in males, whereas Wnt signaling, apoptosis, lipid 
metabolism, and steroid hormone signaling were enriched in females. Thus, we showed for 
the first time that sex impacts the transcriptomic response to HFD in colon and we further 
demonstrated that this manifested in functional changes in the colon. Both sexes showed a 
significant increase of macrophage infiltration upon HFD, with a stronger increase in 
females. Only males presented a significantly increased epithelial cell proliferation upon 
HFD.  
 
Figure 11: E2 regulates a fraction of HFD-induced genes, interestingly almost all of these HFD regulated genes were 
regulated in the opposite direction upon E2 treatment in males. The circadian core clock genes Bmal1 and Npas2 were 
downregulated by HFD and the levels were brought back to normal with E2 treatment. ChIP-seq in human CRC cell lines 
revealed that both ARNTL and NPAS2 had ERβ DNA-binding sites, which suggests ERβ binding and regulation of these 
genes.  
Interestingly, E2 treatment in males affected expression of 30% of the HFD-deregulated 
genes, of which almost all were regulated in the opposite direction upon E2 treatment (Figure 
11A). These genes were involved in pathways related to cell cycle and rhythmic processes. 
E2 opposed the HFD-induced downregulation of both Npas2 and Bmal1 (Figure 11B). The 
circadian clock regulates vital processes involved in colitis and CRC including immune 
response 209, intestinal permeability 210 and cell cycle control 211. BMAL1 has been shown to 
repress chemokines associated with recruitment of pro-inflammatory MΦ 212. Interestingly, 
we found a decreased MΦ infiltration with E2 treatment, which also was evident with ERβ-
selective activation with DPN in both sexes. Moreover, E2 treatment and ERβ-selective 
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ligand activation in males reduced the HFD-induced epithelial cell proliferation. Our 
mechanistic data in human CRC cell lines showed that ERβ could bind to cis-regulatory 
chromatin regions of both BMAL1 and NPAS2 (Figure 11C), which suggest that ERβ could 
act locally in the colon to directly regulate these genes. We confirmed this using our 
ERβKOVil mice, where knockout females showed a significant decrease in Bmal1 and Npas2 
during HFD. 
 
Figure 12: Schematic illustration of the proposed model for estrogen regulation, via ERβ, on the colon microenvironment 
during HFD-induced obesity. Estrogen signaling, via ERβ could modulate the HFD-induced epithelial cell proliferation, 
macrophage infiltration and regulation of core clock gene expression, in a sex-dependent manner. Note: this image contains 
elements that were modified from Servier Medical Art (http://smart.servier.com/), licensed under a Creative Common 
Attribution 3.0 Generic License.    
In conclusion or study show for the first time that estrogen-signaling via ERβ can modulate 
the colon microenvironment during HFD, including regulation of the core clock genes Bmal1 
and Npas2, epithelial cell proliferation and MΦ infiltration, in a sex-dependent manner 
(Figure 12). This study provides new insights how ERβ protects against detrimental effects 
of HFD-induced colon inflammation, and potentially undermines the promotion of CA-
CRC.  
4.4 PAPER IV: THE IMPORTANCE OF SEX IN COLORECTAL CANCER 
BIOMARKER DISCOVERY  
In addition to better CRC preventatives, there is a need for better diagnostic and prognostic 
biomarkers, which could significantly improve the CRC survival rates. Despite the intense 
research, few biomarkers have reached the clinic. The use of gene expression data for 
biomarker discovery has been limited. Gene expression data is usually obtained from small 
sample sizes but with high dimensions and noise, which usually leads to overfitting problems. 
The advances in both omics technologies and bioinformatics have the possibility to improve 
and accelerate current strategies for biomarker discovery. Feature selection in combination 
with machine learning reduces the noise and the high dimension produced by transcriptomic 
analysis, which will help to identify relevant disease-related genes. However, there is a need 
to account for sex, which studies fail to do. CRC presents sex differences in the incidence, 
prognosis, mortality and tumor characteristics. In this study we looked at transcriptomic sex 
differences in paired normal and matched CRC samples (n=24, 18 women and 6 men) and in 
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641 (299 women and 342 men) CRC (COAD and READ) and 51 (28 women and 23 men) 
noncancerous mucosal tissues from TCGA data. We performed feature selection with Vita, 
Boruta and MRMR, and machine learning using random forest to identify sex-specific 
diagnostic biomarkers. Further, we used the TCGA data to perform sex-specific survival 
analysis to identify their prognostic value.  
Interestingly, we found sex differences in the normal colon and CRC transcriptome. The 
differentially expressed genes in the normal colon belonged to pathways involved in bile acid 
secretion, IBD, epithelial cell differentiation, PPAR signaling and carbohydrate-, lipid-, and 
vitamin metabolism. Sex differences in CRC transcriptome were indicative of differences in 
proliferation, immune response and B-cell receptor signaling. Furthermore, our data-driven 
biomarker discovery revealed both common and sex-specific top-ranked biomarkers. 
Biomarkers common between the sexes included previously proposed diagnostic CRC 
biomarkers, such as CLDN1, CEMIP and CDH3 213. Interestingly, we also found sex-specific 
top biomarkers (Figure 13).  This included ETV4, FOXQ1, INHBA and ESM1 in females and 
TRIB3 in males, all of which previously have been reported to be deregulated in CRC. 
Moreover, we also found significant sex-specific prognostic value of previously proposed 
prognostic biomarkers, including CLDN1 and ESM1. CLDN1 and ESM1 were upregulated in 
CRC and CLDN1 showed an unfavorable prognostic value specifically in females, whereas 
ESM1, showed an unfavorable prognostic value specifically in males. Finally, we proposed 
some entirely novel diagnostic and prognostic biomarkers, including TSPAN7 (females, 
unfavorable), SLC25A23 (females, unfavorable) and C2orf88 (males, favorable).  
 
Figure 13: Feature importance ranking for males and females reveals common and sex-specific top diagnostic biomarkers. 
Feature selection is based on Vita, Boruta and mRMR and importance ranking are based on machine learning with random 
forest on COADREAD TCGA data.  
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In conclusion, we identify sex differences in the normal colon and CRC transcriptome, which 
may help explain the sex differences in CRC susceptibility and mortality rates. Interestingly, 
we also found sex-dependent diagnostic and prognostic biomarkers candidates, and we 
propose that including sex considerations and machine learning can improve the discovery of 






5 CONCLUDING REMARKS AND FUTURE 
PERSPECTIVES 
The work presented in this thesis primarily relates to sex differences and the role of intestinal 
epithelial ERβ during colitis and colitis-induced CRC. This section further discusses the 
significance of the findings and future directions.  
CRC is the third most deadly forms of cancer in the Western world. Although screening-
efforts have reduced the overall mortality, the incidence is increasing among young adults. 
The frequency of IBD and obesity are increasing in parallel, which suggests a common 
underlying environmental link between the conditions. This increase is thought to correlate 
to an increased intake of high fat diets, and obesity is a major risk factor for CRC. The risk-
benefit balance of current CRC preventative treatments is poor, and there is a need for safer 
and better preventatives in order to reduce CRC mortality. There is evidence that ERβ is 
protective against CRC and natural ERβ-selective agonist has been proven safe in phase II 
clinical trials 214, 215, however the underlying protective mechanism needs to be elucidated. 
In paper I we showed that intestinal epithelial ERβ is protective against colitis and colitis-
associated tumor formation in both sexes. Furthermore, in paper III estrogen signaling via 
ERβ could protect against HFD-induced detrimental effects on the colon 
microenvironment. ERβ-selective activation reduced the HFD-induced epithelial cell 
proliferation in males and macrophage infiltration in both sexes. This protective effect 
could, in part, be accompanied by ERβ-induced modulation of the gut microbiota, and we 
showed that intestinal epithelial ERβ modulated the gut microbiota during experimental 
colitis in paper II.  
In paper I the underlying protective mechanism by ERβ involved a cross talk with 
TNFα/NFκB signaling and a proposed direct ERβ-mediated repression of NFκB activators, 
resulting in reduced inflammatory signaling and tumor formation. This was accompanied 
by an altered abundance of SCFAs- and H2S-producing bacteria by ERβ, as shown in 
paper II. SCFAs and H2S are bacterial metabolites that present potential detrimental or 
beneficial effects for the intestinal epithelium. In paper III, we showed that ERβ activation 
reduced the HFD-induced deregulation of core clock gene expression. The circadian clock 
is important to keep intestinal homeostasis, and disruption can modulate proliferation, 
intestinal permeability, the microbiota composition and the immune system 210, 216-219.  
Interestingly, the circadian clock has also been shown to be dysregulated in mice with DSS-
induced experimental colitis, which suggests a common underlying disease mechanism 
with HFD-induced colon inflammation. In fact, Bmal1 knockout mice present increased 
severity of DSS-induced colitis 220. Furthermore, myeloid cell-specific deletion of Bmal1 
results in increased expression of Ccl2 in blood monocytes and increased serum levels 
during HFD-induced obesity 212. This increased expression can recruit pro-inflammatory 
macrophages. In paper I, we did see an increase of Ccl2 upon loss of intestinal epithelial 
ERβ during colitis-induced CRC in males, which may contribute to an altered tumor 
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microenvironment and enhanced tumor formation. Since we showed that the Bmal1 gene 
has a cis-chromatin ERβ-binding site, it is possible that ERβ directly regulates the intestinal 
circadian clock during colitis and thereby attenuates AOM/DSS-induced tumor formation. 
The gut microbiota and the TLR expression are also under circadian regulation, and 
disruption of these rhythms can result in regulation of bacterial metabolites that can influence 
the intestinal homeostasis.  
Another important finding, are the significant sex differences seen in all papers. In paper I, 
intestinal epithelial ERβ protected against colitis-induced tumor formation in a sex-
dependent manner. ERβKOVil male mice developed significantly more tumors whereas 
ERβKOVil female mice developed significantly larger tumors compared to its WT 
counterparts. Furthermore, ERβKOVil females presented more ulcerated areas and a delayed 
ulcer healing, whereas ERβKOVil males presented increased expression of several NFκB-
induced genes. Unexpectedly, male mice responded stronger to the loss of intestinal 
epithelial ERβ compared to females, both in terms of inflammatory signaling and tumor 
development. Estrogen is not though as a male hormone, however E1 and DHEA, a precursor 
of 3β-Adiol and a proposed ERβ ligand is present in males. Furthermore, the mice were given 
normal chow, which contains phytoestrogens that activate ERβ. Thus, ERβ would be active 
in both sexes. Interestingly, in paper III the CD and HFD did not contain any phytoestrogens 
and we noted significant sex differences in the colon transcriptome during both dietary 
conditions (especially during CD), and in the response to HFD. Furthermore, we observed 
sex differences in the microbiome, which may promote or prevent the response to 
experimentally-induced colitis. Interestingly, sex differences were also seen in the human 
normal colonic and CRC transcriptome in paper IV. The sex differences of the normal colon 
were overrepresented among pathways related to bile acid secretion, IBD, epithelial cell 
differentiation, PPAR signaling and carbohydrate-, lipid-, and vitamin metabolism, all known 
to be dysregulated in CRC. We also noted sex differences in the CRC transcriptome, mostly 
related to immune response and B-cell receptor signaling. Although ERβ expression is lost in 
CRC, we still noted sex differences in the CRC transcriptome as well as among proposed 
diagnostic and prognostic biomarkers. The sex differences may be mediated by ERβ activity 
in surrounding normal epithelium or in the immune system, or be unrelated to ERβ. In paper 
I-III we showed that epithelial ERβ could modulate the microbiota composition and 
inflammatory signaling, which in turn could shape the tumor microenvironment, and thereby 
impact tumor gene expression. 
Another interesting finding in paper I is the enhanced ERβ transactivation by TNFα. ERβ is 
expressed at low levels in the intestinal epithelial cells, and it has been unclear if this low 
expression has a functional role. Here we propose that the inflammatory state amplified the 
activity of ERβ, which in turn could suppresses the colon inflammation and tumor 
development induced by HFD and AOM/DSS. All together our results support the notion 
that an ERβ agonist may constitute a suitable chemopreventive approach against CA-CRC. 
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5.1 FUTURE PERSPECTIVES 
The transactivation of ERβ was enhanced by TNFα suggesting that the inflammatory state 
could enhance the protective function of ERβ. In addition to TNFα, LPS from gram-negative 
bacteria can activate NFκB signaling and it is possible that the LPS-induced inflammatory 
signaling also can enhance transactivation of ERβ. In this case, ERβ in turn, could repress 
the LPS-induced inflammatory response. Interestingly, colonic ERβ expression is reduced in 
antibiotic-treated mice 221, suggesting that the gut microbiome and its metabolites or the 
overproduction of glucocorticoids in microbiota deficient mice might regulate ERβ 
expression. Characterization of the crosstalk with intestinal epithelial ERβ and LPS-induced 
inflammatory signaling will improve the understanding of the ERβ-mediated protective 
mechanism via crosstalk with NFκB. Further studies investigating how ERβ and sex impacts 
the p65 cistrome in the colon of AOM/DSS treated mice can lead to improved understanding 
of the crosstalk between ERβ and NFκB. The protective mechanism of ERβ during 
AOM/DSS-induced tumor formation can further be investigated by transcriptomic profiling 
of the colon from WT and ERβKOVil mice.  
Several NRs have been associated with colon inflammation and an increasing number of 
NRs have been validated as potential drug targets for IBD. An improved understanding and 
identification of novel crosstalk mechanisms can ultimately change the field from a single 
targeting approach to a dual NR targeting approach. Alternative targeting strategies, such as 
allosteric ligands and ligands targeting NR related protein-protein interactions, may 
improve current therapeutic strategies. The BA receptor FXR regulates BA homeostasis 
and its expression in the intestine is associated with anti-inflammatory effects 85. 
Interestingly, sex has been reported to affect BA pool composition and size 222, which 
indicate a role for estrogen in the regulation of the BA homeostasis. Interestingly, FXR 
activation has been shown to suppress the expression of the estrogen sulfotransferase 
(SULT1E), which is responsible for metabolic estrogen inactivation 223. Moreover, ERα and 
glucocorticoid receptor (GR) has been shown to crosstalk and to regulate each other’s 
chromatin binding in breast cancer cell lines 224. In addition to the direct crosstalk, GR can 
also indirectly affect ERα response through regulation of SULT1E 225. Characterization of a 
possible crosstalk between ERβ, FXR, GR, and other NRs in the colon may lead to improved 
therapeutic strategies. 
Furthermore, intestinal epithelial ERβ modulates the gut microbiota and probiotics are 
promising in the prevention and treatment of CRC. However to further characterize the 
impact of ERβ on the microbiome, larger studies with metagenomics profiling is needed to 
improve the taxonomic resolution and to get microbiome functional profiles.  
Moreover, we found that intestinal epithelial ERβ regulated the circadian clock gene 
expression, which is important to keep intestinal homeostasis. The circadian clock is 
dysregulated in both IBD and CRC. Recent studies have shown that clock gene disruption is 
an early event in IBD, since clock gene expression was found to be significantly lower even 
in non-inflamed mucosa of patients with IBD compared to controls 226. Restoring the 
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circadian clock by safe therapies, such as selective activation of ERβ, can be an ideal 
approach for IBD and in the prevention of CA-CRC. However, further studies are needed to 
characterize the role of ERβ in the regulation of the circadian rhythmicity in the colon. 
Studying mice at different zeitgeber times are thus crucial in order to understand how 
intestinal ERβ regulates the impaired circadian rhythmicity during HFD and 
experimentally-induced colitis.  
Worth noting is that some of the sex differences reported throughout the thesis were related to 
immune cell response, including B-cell receptor signaling (both in mouse and humans). 
Although estrogen and ERβ is known to impact the immune system, the vast majority of 
immune-related genes are located on chromosome X and skewed X chromosome inactivation 
can lead to sex-biases in inflammatory diseases. In order to detail estrogen related sex 
differences, a larger study including normal colon and CRC from pre- and postmenopausal 
women would be needed. However, ERβ is also expressed in various immune cells and may 
impact the immune response. To characterize the role of ERβ expression in immune cells T 
or B cell-specific deletion of ERβ can be utilized. 
After characterization of the mechanism, the next step would be to screen for a safe ERβ-
selective agonist and test it in clinical trials to see if it can reduce the inflammation in patients 
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